Trastuzumab
Information
- Drug Name
- Trastuzumab
- Description
- Entry(CIViC)
- 65
CIViC
| Disease | Mutation | EL | ET | ED | CS | VO | TR | Pubmed | Links |
|---|---|---|---|---|---|---|---|---|---|
| breast cancer |
ERBB2 AMPLIFICATION ( ENST00000269571.10 ) ERBB2 AMPLIFICATION ( ENST00000269571.10 ) |
D |
Predictive
|
Supports
|
Sensitivity/Response | Somatic | 3 | 16091755 | Detail |
| Her2-receptor positive breast cancer |
ERBB2 AMPLIFICATION ( ENST00000269571.10 ) ERBB2 AMPLIFICATION ( ENST00000269571.10 ) |
B |
Predictive
|
Supports
|
Sensitivity/Response | Somatic | 4 | 22493419 | Detail |
| Her2-receptor positive breast cancer |
ERBB2 AMPLIFICATION ( ENST00000269571.10 ) ERBB2 AMPLIFICATION ( ENST00000269571.10 ) |
B |
Predictive
|
Does Not Support
|
Sensitivity/Response | Somatic | 4 | 26255196 | Detail |
| Her2-receptor positive breast cancer |
ERBB2 AMPLIFICATION ( ENST00000269571.10 ) ERBB2 AMPLIFICATION ( ENST00000269571.10 ) |
B |
Predictive
|
Supports
|
Sensitivity/Response | Somatic | 4 | 20124187 | Detail |
| Her2-receptor positive breast cancer |
ERBB2 AMPLIFICATION ( ENST00000269571.10 ) ERBB2 AMPLIFICATION ( ENST00000269571.10 ) |
B |
Predictive
|
Supports
|
Sensitivity/Response | Somatic | 3 | 25370464 | Detail |
| gastric adenocarcinoma |
ERBB2 AMPLIFICATION ( ENST00000269571.10 ) ERBB2 AMPLIFICATION ( ENST00000269571.10 ) |
B |
Predictive
|
Supports
|
Sensitivity/Response | Somatic | 4 | 20728210 | Detail |
| lung non-small cell carcinoma |
ERBB2 AMPLIFICATION ( ENST00000269571.10 ) ERBB2 AMPLIFICATION ( ENST00000269571.10 ) |
B |
Predictive
|
Does Not Support
|
Sensitivity/Response | Somatic | 2 | 14679114 | Detail |
| lung non-small cell carcinoma |
ERBB2 AMPLIFICATION ( ENST00000269571.10 ) ERBB2 AMPLIFICATION ( ENST00000269571.10 ) |
B |
Predictive
|
Does Not Support
|
Sensitivity/Response | Somatic | 3 | 14967075 | Detail |
| lung adenocarcinoma | ERBB2 KINASE DOMAIN MUTATION ERBB2 KINASE DOMAIN MUTATION | C |
Predictive
|
Supports
|
Sensitivity/Response | Somatic | 4 | 26598547 | Detail |
| lung small cell carcinoma |
ERBB2 AMPLIFICATION ( ENST00000269571.10 ) ERBB2 AMPLIFICATION ( ENST00000269571.10 ) |
C |
Predictive
|
Supports
|
Sensitivity/Response | Somatic | 4 | 25601188 | Detail |
| Her2-receptor positive breast cancer |
ERBB2 AMPLIFICATION ( ENST00000269571.10 ) ERBB2 AMPLIFICATION ( ENST00000269571.10 ) |
B |
Predictive
|
Supports
|
Sensitivity/Response | Somatic | 5 | 25693012 | Detail |
| breast cancer |
FCGR3A p.Phe176Val (p.F176V) ( ENST00000367967.8, ENST00000436743.7, ENST00000699395.1, ENST00000699397.1, ENST00000699399.1, ENST00000699401.1, ENST00000699396.1, ENST00000426740.8, ENST00000699400.1, ENST00000443193.6, ENST00000699398.1 ) FCGR3A p.Phe176Val (p.F176V) ( ENST00000367967.8, ENST00000426740.8, ENST00000436743.7, ENST00000443193.6, ENST00000699395.1, ENST00000699396.1, ENST00000699397.1, ENST00000699398.1, ENST00000699399.1, ENST00000699400.1, ENST00000699401.1 ) |
B |
Predictive
|
Does Not Support
|
N/A | Common Germline | 4 | 24989892 | Detail |
| endometrial serous adenocarcinoma |
ERBB2 AMPLIFICATION ( ENST00000269571.10 ) ERBB2 AMPLIFICATION ( ENST00000269571.10 ) |
C |
Predictive
|
Supports
|
Sensitivity/Response | Somatic | 4 | 18555254 | Detail |
| endometrial cancer |
ERBB2 AMPLIFICATION ( ENST00000269571.10 ) ERBB2 AMPLIFICATION ( ENST00000269571.10 ) |
B |
Predictive
|
Does Not Support
|
Sensitivity/Response | Somatic | 2 | 19840887 | Detail |
| Her2-receptor positive breast cancer |
ERBB2 AMPLIFICATION ( ENST00000269571.10 ) ERBB2 AMPLIFICATION ( ENST00000269571.10 ) |
A |
Predictive
|
Supports
|
Sensitivity/Response | Somatic | 4 | 26874901 | Detail |
| Her2-receptor positive breast cancer |
ERBB2 AMPLIFICATION ( ENST00000269571.10 ) ERBB2 AMPLIFICATION ( ENST00000269571.10 ) |
A |
Predictive
|
Supports
|
Sensitivity/Response | Somatic | 4 | 16236737 | Detail |
| Her2-receptor positive breast cancer |
ERBB2 AMPLIFICATION ( ENST00000269571.10 ) ERBB2 AMPLIFICATION ( ENST00000269571.10 ) |
B |
Predictive
|
Supports
|
Sensitivity/Response | Somatic | 4 | 19289619 | Detail |
| colon cancer |
ERBB2 p.Val842Ile (p.V842I) ( ENST00000541774.5, ENST00000584450.5, ENST00000584601.5, ENST00000269571.10, ENST00000406381.6, ENST00000445658.6 ) ERBB2 p.Val842Ile (p.V842I) ( ENST00000584450.5, ENST00000269571.10, ENST00000406381.6, ENST00000445658.6, ENST00000541774.5, ENST00000584601.5 ) |
D |
Predictive
|
Supports
|
Sensitivity/Response | Somatic | 4 | 26243863 | Detail |
| colon cancer |
ERBB2 p.Leu755Ser (p.L755S) ( ENST00000269571.10, ENST00000406381.6, ENST00000445658.6, ENST00000541774.5, ENST00000584450.5, ENST00000584601.5 ) ERBB2 p.Leu755Ser (p.L755S) ( ENST00000269571.10, ENST00000406381.6, ENST00000445658.6, ENST00000541774.5, ENST00000584450.5, ENST00000584601.5 ) |
D |
Predictive
|
Supports
|
Sensitivity/Response | Somatic | 4 | 26243863 | Detail |
| colon cancer |
ERBB2 p.Val777Leu (p.V777L) ( ENST00000269571.10, ENST00000406381.6, ENST00000445658.6, ENST00000541774.5, ENST00000584450.5, ENST00000584601.5 ) ERBB2 p.Val777Leu (p.V777L) ( ENST00000584601.5, ENST00000269571.10, ENST00000406381.6, ENST00000445658.6, ENST00000541774.5, ENST00000584450.5 ) |
D |
Predictive
|
Supports
|
Sensitivity/Response | Somatic | 4 | 26243863 | Detail |
| colon cancer |
ERBB2 p.Leu866Met (p.L866M) ( ENST00000541774.5, ENST00000584601.5, ENST00000269571.10, ENST00000445658.6, ENST00000584450.5, ENST00000406381.6 ) ERBB2 p.Leu866Met (p.L866M) ( ENST00000269571.10, ENST00000406381.6, ENST00000445658.6, ENST00000541774.5, ENST00000584450.5, ENST00000584601.5 ) |
D |
Predictive
|
Supports
|
Sensitivity/Response | Somatic | 4 | 26243863 | Detail |
| colon cancer | ERBB2 S310F/Y ERBB2 S310F/Y | D |
Predictive
|
Supports
|
Sensitivity/Response | Somatic | 4 | 26243863 | Detail |
| Her2-receptor positive breast cancer |
PTEN DELETION ( ENST00000371953.8 ) PTEN DELETION ( ENST00000371953.8 ) |
D |
Predictive
|
Supports
|
Resistance | Somatic | 2 | 17936563 | Detail |
| Her2-receptor positive breast cancer | PIK3CA MUTATION PIK3CA MUTATION | B |
Predictive
|
Supports
|
Resistance | Somatic | 2 | 17936563 | Detail |
| Her2-receptor positive breast cancer |
PTEN DELETION ( ENST00000371953.8 ) PTEN DELETION ( ENST00000371953.8 ) |
B |
Predictive
|
Supports
|
Resistance | Somatic | 3 | 20813970 | Detail |
| Her2-receptor positive breast cancer |
PTEN DELETION ( ENST00000371953.8 ) PTEN DELETION ( ENST00000371953.8 ) |
B |
Predictive
|
Does Not Support
|
Resistance | Somatic | 3 | 20813970 | Detail |
| Her2-receptor positive breast cancer |
ERBB2 AMPLIFICATION ( ENST00000269571.10 ) ERBB2 AMPLIFICATION ( ENST00000269571.10 ) |
B |
Predictive
|
Supports
|
Sensitivity/Response | Somatic | 4 | 22149875 | Detail |
| Her2-receptor positive breast cancer |
ERBB2 AMPLIFICATION ( ENST00000269571.10 ) ERBB2 AMPLIFICATION ( ENST00000269571.10 ) |
B |
Predictive
|
Supports
|
Sensitivity/Response | Somatic | 4 | 22257673 | Detail |
| Her2-receptor positive breast cancer |
ERBB2 AMPLIFICATION ( ENST00000269571.10 ) ERBB2 AMPLIFICATION ( ENST00000269571.10 ) |
D |
Predictive
|
Supports
|
Sensitivity/Response | Somatic | 4 | 23204226 | Detail |
| Her2-receptor positive breast cancer |
BIRC5 OVEREXPRESSION ( ENST00000301633.8 ) BIRC5 OVEREXPRESSION ( ENST00000301633.8 ) |
B |
Predictive
|
Supports
|
Resistance | Somatic | 4 | 23204226 | Detail |
| Her2-receptor positive breast cancer |
PIK3CA p.Glu545Lys (p.E545K) ( ENST00000263967.4, ENST00000643187.1 ) PIK3CA p.Glu545Lys (p.E545K) ( ENST00000263967.4, ENST00000643187.1 ) |
D |
Predictive
|
Supports
|
Resistance | Somatic | 2 | 18829560 | Detail |
| Her2-receptor positive breast cancer |
PTEN DELETION ( ENST00000371953.8 ) PTEN DELETION ( ENST00000371953.8 ) |
D |
Predictive
|
Supports
|
Sensitivity/Response | Somatic | 3 | 15324695 | Detail |
| gastric adenocarcinoma |
ERBB2 AMPLIFICATION ( ENST00000269571.10 ) ERBB2 AMPLIFICATION ( ENST00000269571.10 ) |
A |
Predictive
|
Supports
|
Sensitivity/Response |
N/A
|
4 | 20728210 | Detail |
| Her2-receptor positive breast cancer |
PIK3CA p.His1047Arg (p.H1047R) ( ENST00000263967.4, ENST00000643187.1 ) PIK3CA p.His1047Arg (p.H1047R) ( ENST00000263967.4, ENST00000643187.1 ) |
D |
Predictive
|
Supports
|
Sensitivity/Response | Somatic | 3 | 22294718 | Detail |
| Her2-receptor positive breast cancer |
ERBB2 AMPLIFICATION ( ENST00000269571.10 ) ERBB2 AMPLIFICATION ( ENST00000269571.10 ) |
D |
Predictive
|
Supports
|
Sensitivity/Response | Somatic | 2 | 19874578 | Detail |
| colorectal cancer |
ERBB2 AMPLIFICATION ( ENST00000269571.10 ) ERBB2 AMPLIFICATION ( ENST00000269571.10 ) |
B |
Predictive
|
Supports
|
Sensitivity/Response |
N/A
|
4 | 27108243 | Detail |
| scrotum Paget's disease |
ERBB2 AMPLIFICATION ( ENST00000269571.10 ) ERBB2 AMPLIFICATION ( ENST00000269571.10 ) |
C |
Predictive
|
Supports
|
Sensitivity/Response | Somatic | 2 | 25692060 | Detail |
| Her2-receptor positive breast cancer |
PTEN DELETION ( ENST00000371953.8 ) PTEN DELETION ( ENST00000371953.8 ) |
B |
Predictive
|
Supports
|
Resistance | Somatic | 2 | 21594665 | Detail |
| breast cancer |
PTEN DELETION ( ENST00000371953.8 ) PTEN DELETION ( ENST00000371953.8 ) |
B |
Predictive
|
Supports
|
Resistance | Somatic | 2 | 21594665 | Detail |
| breast cancer | PIK3CA MUTATION PIK3CA MUTATION | B |
Predictive
|
Supports
|
Resistance | Somatic | 3 | 21594665 | Detail |
| Her2-receptor positive breast cancer | PIK3CA MUTATION PIK3CA MUTATION | B |
Predictive
|
Supports
|
Resistance | Somatic | 3 | 21594665 | Detail |
| breast cancer |
PIK3CA p.His1047Arg (p.H1047R) ( ENST00000263967.4, ENST00000643187.1 ) PIK3CA p.His1047Arg (p.H1047R) ( ENST00000263967.4, ENST00000643187.1 ) |
D |
Predictive
|
Supports
|
Resistance | Somatic | 3 | 20453058 | Detail |
| colorectal adenocarcinoma |
ERBB2 p.Leu755Ser (p.L755S) ( ENST00000269571.10, ENST00000406381.6, ENST00000445658.6, ENST00000541774.5, ENST00000584450.5, ENST00000584601.5 ) ERBB2 p.Leu755Ser (p.L755S) ( ENST00000269571.10, ENST00000406381.6, ENST00000445658.6, ENST00000541774.5, ENST00000584450.5, ENST00000584601.5 ) |
C |
Predictive
|
Does Not Support
|
Sensitivity/Response | Somatic | 3 | 27626067 | Detail |
| Her2-receptor positive breast cancer |
ERBB2 AMPLIFICATION ( ENST00000269571.10 ) ERBB2 AMPLIFICATION ( ENST00000269571.10 ) |
B |
Predictive
|
Supports
|
Sensitivity/Response | Somatic | 5 | 11248153 | Detail |
| Her2-receptor positive breast cancer |
ERBB2 AMPLIFICATION ( ENST00000269571.10 ) ERBB2 AMPLIFICATION ( ENST00000269571.10 ) |
B |
Predictive
|
Supports
|
Sensitivity/Response | Somatic | 5 | 15911866 | Detail |
| pancreatic cancer | ERBB2 OVEREXPRESSION ERBB2 OVEREXPRESSION | B |
Predictive
|
Does Not Support
|
Sensitivity/Response | Somatic | 4 | 22374460 | Detail |
| pancreatic cancer | ERBB2 OVEREXPRESSION ERBB2 OVEREXPRESSION | B |
Predictive
|
Does Not Support
|
Sensitivity/Response | Somatic | 4 | 15581051 | Detail |
| lung non-small cell carcinoma | ERBB2 MUTATION ERBB2 MUTATION | B |
Predictive
|
Supports
|
Sensitivity/Response | Somatic | 2 | 29320312 | Detail |
| colorectal cancer |
ERBB2 AMPLIFICATION ( ENST00000269571.10 ) ERBB2 AMPLIFICATION ( ENST00000269571.10 ) |
B |
Predictive
|
Supports
|
Sensitivity/Response |
N/A
|
4 | 29320312 | Detail |
| bladder carcinoma |
ERBB2 AMPLIFICATION ( ENST00000269571.10 ) ERBB2 AMPLIFICATION ( ENST00000269571.10 ) |
B |
Predictive
|
Supports
|
Sensitivity/Response |
N/A
|
3 | 29320312 | Detail |
| biliary tract cancer |
ERBB2 AMPLIFICATION ( ENST00000269571.10 ) ERBB2 AMPLIFICATION ( ENST00000269571.10 ) |
B |
Predictive
|
Supports
|
Sensitivity/Response |
N/A
|
2 | 29320312 | Detail |
| salivary gland carcinoma |
ERBB2 AMPLIFICATION ( ENST00000269571.10 ) ERBB2 AMPLIFICATION ( ENST00000269571.10 ) |
B |
Predictive
|
Supports
|
Sensitivity/Response |
N/A
|
2 | 29320312 | Detail |
| pancreatic cancer |
ERBB2 AMPLIFICATION ( ENST00000269571.10 ) ERBB2 AMPLIFICATION ( ENST00000269571.10 ) |
B |
Predictive
|
Supports
|
Sensitivity/Response |
N/A
|
2 | 29320312 | Detail |
| uterine cancer |
ERBB2 AMPLIFICATION ( ENST00000269571.10 ) ERBB2 AMPLIFICATION ( ENST00000269571.10 ) |
B |
Predictive
|
Does Not Support
|
Sensitivity/Response |
N/A
|
2 | 29320312 | Detail |
| salivary gland cancer | ERBB2 OVEREXPRESSION ERBB2 OVEREXPRESSION | C |
Predictive
|
Supports
|
Sensitivity/Response |
N/A
|
2 | 23826550 | Detail |
| salivary gland cancer | ERBB2 OVEREXPRESSION ERBB2 OVEREXPRESSION | C |
Predictive
|
Supports
|
Sensitivity/Response |
N/A
|
3 | 20504363 | Detail |
| breast cancer |
PTEN DELETION ( ENST00000371953.8 ) PTEN DELETION ( ENST00000371953.8 ) |
B |
Predictive
|
Supports
|
Resistance | Somatic | 1 | 24387334 | Detail |
| breast cancer | AKT2 EXPRESSION AKT2 EXPRESSION | B |
Predictive
|
Supports
|
Sensitivity/Response | Somatic | 3 | 22842582 | Detail |
| colorectal cancer |
ERBB2 AMPLIFICATION ( ENST00000269571.10 ) ERBB2 AMPLIFICATION ( ENST00000269571.10 ) |
B |
Predictive
|
Supports
|
Sensitivity/Response | Somatic | 3 | 30857956 | Detail |
| cholangiocarcinoma |
ERBB2 AMPLIFICATION ( ENST00000269571.10 ) ERBB2 AMPLIFICATION ( ENST00000269571.10 ) |
C |
Predictive
|
Supports
|
Sensitivity/Response | Somatic | 3 | 31453370 | Detail |
| gastric adenocarcinoma |
PTEN DELETION ( ENST00000371953.8 ) PTEN DELETION ( ENST00000371953.8 ) |
B |
Predictive
|
Supports
|
Resistance |
N/A
|
2 | 25300346 | Detail |
| breast cancer | ERBB4 NUCLEAR TRANSLOCATION ERBB4 NUCLEAR TRANSLOCATION | D |
Predictive
|
Supports
|
Resistance |
N/A
|
2 | 25153719 | Detail |
| breast cancer | ERBB4 EXPRESSION ERBB4 EXPRESSION | D |
Predictive
|
Supports
|
Resistance |
N/A
|
2 | 25153719 | Detail |
| Her2-receptor positive breast cancer |
ERBB2 AMPLIFICATION ( ENST00000269571.10 ) ERBB2 AMPLIFICATION ( ENST00000269571.10 ) |
B |
Predictive
|
Supports
|
Sensitivity/Response | Somatic | 2 | 25537159 | Detail |
| breast cancer | PTEN EXPRESSION PTEN EXPRESSION | B |
Predictive
|
Supports
|
Sensitivity/Response | Somatic | 3 | 16404430 | Detail |
Annotation
| Description | Associated Genes | Associated Variants | Sensitivity | Supported | Source | Links |
|---|---|---|---|---|---|---|
| In-vitro studies using ERBB2 over-expressing breas... | ERBB2 |
ERBB2 AMPLIFICATION ( ENST00000269571.10 ) ERBB2 AMPLIFICATION ( ENST00000269571.10 ) |
Sensitivity | true | CIViC Evidence | detail |
| In light of results showing increased PFS using mA... | ERBB2 |
ERBB2 AMPLIFICATION ( ENST00000269571.10 ) ERBB2 AMPLIFICATION ( ENST00000269571.10 ) |
Sensitivity | true | CIViC Evidence | detail |
| This Phase III trial compared the activity of lapa... | ERBB2 |
ERBB2 AMPLIFICATION ( ENST00000269571.10 ) ERBB2 AMPLIFICATION ( ENST00000269571.10 ) |
Sensitivity | false | CIViC Evidence | detail |
| This Phase III study (EGF104900) was motivated by ... | ERBB2 |
ERBB2 AMPLIFICATION ( ENST00000269571.10 ) ERBB2 AMPLIFICATION ( ENST00000269571.10 ) |
Sensitivity | true | CIViC Evidence | detail |
| Trastuzumab resistance is thought to consist of mu... | ERBB2 |
ERBB2 AMPLIFICATION ( ENST00000269571.10 ) ERBB2 AMPLIFICATION ( ENST00000269571.10 ) |
Sensitivity | true | CIViC Evidence | detail |
| ToGA, a Phase III study (NCT01041404) addressed us... | ERBB2 |
ERBB2 AMPLIFICATION ( ENST00000269571.10 ) ERBB2 AMPLIFICATION ( ENST00000269571.10 ) |
Sensitivity | true | CIViC Evidence | detail |
| In this phase II trial with 2 arms, 103 patients w... | ERBB2 |
ERBB2 AMPLIFICATION ( ENST00000269571.10 ) ERBB2 AMPLIFICATION ( ENST00000269571.10 ) |
Sensitivity | false | CIViC Evidence | detail |
| In this phase II trial a small group of patients w... | ERBB2 |
ERBB2 AMPLIFICATION ( ENST00000269571.10 ) ERBB2 AMPLIFICATION ( ENST00000269571.10 ) |
Sensitivity | false | CIViC Evidence | detail |
| This was a retrospective study of patients with ad... | ERBB2 | ERBB2 KINASE DOMAIN MUTATION ERBB2 KINASE DOMAIN MUTATION | Sensitivity | true | CIViC Evidence | detail |
| This report details 2 case studies in relapsed HER... | ERBB2 |
ERBB2 AMPLIFICATION ( ENST00000269571.10 ) ERBB2 AMPLIFICATION ( ENST00000269571.10 ) |
Sensitivity | true | CIViC Evidence | detail |
| CLEOPATRA (NCT00567190) was a Phase III, randomize... | ERBB2 |
ERBB2 AMPLIFICATION ( ENST00000269571.10 ) ERBB2 AMPLIFICATION ( ENST00000269571.10 ) |
Sensitivity | true | CIViC Evidence | detail |
| 1325 HER2-positive breast cancer patients treated ... | FCGR3A |
FCGR3A p.Phe176Val (p.F176V) ( ENST00000367967.8, ENST00000436743.7, ENST00000699395.1, ENST00000699397.1, ENST00000699399.1, ENST00000699401.1, ENST00000699396.1, ENST00000426740.8, ENST00000699400.1, ENST00000443193.6, ENST00000699398.1 ) FCGR3A p.Phe176Val (p.F176V) ( ENST00000367967.8, ENST00000426740.8, ENST00000436743.7, ENST00000443193.6, ENST00000699395.1, ENST00000699396.1, ENST00000699397.1, ENST00000699398.1, ENST00000699399.1, ENST00000699400.1, ENST00000699401.1 ) |
N/A | false | CIViC Evidence | detail |
| HER2 expression in uterine serous papillary carcin... | ERBB2 |
ERBB2 AMPLIFICATION ( ENST00000269571.10 ) ERBB2 AMPLIFICATION ( ENST00000269571.10 ) |
Sensitivity | true | CIViC Evidence | detail |
| This phase II single arm study assessed trastuzuma... | ERBB2 |
ERBB2 AMPLIFICATION ( ENST00000269571.10 ) ERBB2 AMPLIFICATION ( ENST00000269571.10 ) |
Sensitivity | false | CIViC Evidence | detail |
| In this two arm, Phase III study (NCT00878709) of ... | ERBB2 |
ERBB2 AMPLIFICATION ( ENST00000269571.10 ) ERBB2 AMPLIFICATION ( ENST00000269571.10 ) |
Sensitivity | true | CIViC Evidence | detail |
| HERA was a Phase III trial assessing application o... | ERBB2 |
ERBB2 AMPLIFICATION ( ENST00000269571.10 ) ERBB2 AMPLIFICATION ( ENST00000269571.10 ) |
Sensitivity | true | CIViC Evidence | detail |
| In this Phase III trial, trastuzumab-based treatme... | ERBB2 |
ERBB2 AMPLIFICATION ( ENST00000269571.10 ) ERBB2 AMPLIFICATION ( ENST00000269571.10 ) |
Sensitivity | true | CIViC Evidence | detail |
| Colon cancer patient derived xenografts with HER2 ... | ERBB2 |
ERBB2 p.Val842Ile (p.V842I) ( ENST00000541774.5, ENST00000584450.5, ENST00000584601.5, ENST00000269571.10, ENST00000406381.6, ENST00000445658.6 ) ERBB2 p.Val842Ile (p.V842I) ( ENST00000584450.5, ENST00000269571.10, ENST00000406381.6, ENST00000445658.6, ENST00000541774.5, ENST00000584601.5 ) |
Sensitivity | true | CIViC Evidence | detail |
| Colon cancer patient derived xenografts with HER2 ... | ERBB2 |
ERBB2 p.Leu755Ser (p.L755S) ( ENST00000269571.10, ENST00000406381.6, ENST00000445658.6, ENST00000541774.5, ENST00000584450.5, ENST00000584601.5 ) ERBB2 p.Leu755Ser (p.L755S) ( ENST00000269571.10, ENST00000406381.6, ENST00000445658.6, ENST00000541774.5, ENST00000584450.5, ENST00000584601.5 ) |
Sensitivity | true | CIViC Evidence | detail |
| Colon cancer patient derived xenografts with HER2 ... | ERBB2 |
ERBB2 p.Val777Leu (p.V777L) ( ENST00000269571.10, ENST00000406381.6, ENST00000445658.6, ENST00000541774.5, ENST00000584450.5, ENST00000584601.5 ) ERBB2 p.Val777Leu (p.V777L) ( ENST00000584601.5, ENST00000269571.10, ENST00000406381.6, ENST00000445658.6, ENST00000541774.5, ENST00000584450.5 ) |
Sensitivity | true | CIViC Evidence | detail |
| Colon cancer patient derived xenografts with HER2 ... | ERBB2 |
ERBB2 p.Leu866Met (p.L866M) ( ENST00000541774.5, ENST00000584601.5, ENST00000269571.10, ENST00000445658.6, ENST00000584450.5, ENST00000406381.6 ) ERBB2 p.Leu866Met (p.L866M) ( ENST00000269571.10, ENST00000406381.6, ENST00000445658.6, ENST00000541774.5, ENST00000584450.5, ENST00000584601.5 ) |
Sensitivity | true | CIViC Evidence | detail |
| Colon cancer patient derived xenografts with HER2 ... | ERBB2 | ERBB2 S310F/Y ERBB2 S310F/Y | Sensitivity | true | CIViC Evidence | detail |
| A large-scale RNAi genetic sereen in HER2 overexpr... | PTEN |
PTEN DELETION ( ENST00000371953.8 ) PTEN DELETION ( ENST00000371953.8 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| The HER2 overexpressing breast cancer cell line BT... | PIK3CA | PIK3CA MUTATION PIK3CA MUTATION | Resitance or Non-Reponse | true | CIViC Evidence | detail |
| A subgroup of HER2-positive breast cancer patients... | PTEN |
PTEN DELETION ( ENST00000371953.8 ) PTEN DELETION ( ENST00000371953.8 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| While some reports indicate PTEN loss is associate... | PTEN |
PTEN DELETION ( ENST00000371953.8 ) PTEN DELETION ( ENST00000371953.8 ) |
Resitance or Non-Reponse | false | CIViC Evidence | detail |
| In a randomized phase 3 trial, HER2 positive metas... | ERBB2 |
ERBB2 AMPLIFICATION ( ENST00000269571.10 ) ERBB2 AMPLIFICATION ( ENST00000269571.10 ) |
Sensitivity | true | CIViC Evidence | detail |
| In a randomized open label phase 3 study (NCT00553... | ERBB2 |
ERBB2 AMPLIFICATION ( ENST00000269571.10 ) ERBB2 AMPLIFICATION ( ENST00000269571.10 ) |
Sensitivity | true | CIViC Evidence | detail |
| In 5 trastuzumab resistant HER2 overexpressing bre... | ERBB2 |
ERBB2 AMPLIFICATION ( ENST00000269571.10 ) ERBB2 AMPLIFICATION ( ENST00000269571.10 ) |
Sensitivity | true | CIViC Evidence | detail |
| 13 HER2 breast cancer patients were treated with t... | BIRC5 |
BIRC5 OVEREXPRESSION ( ENST00000301633.8 ) BIRC5 OVEREXPRESSION ( ENST00000301633.8 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| PI3K mutant E545K was overexpressed in the trastuz... | PIK3CA |
PIK3CA p.Glu545Lys (p.E545K) ( ENST00000263967.4, ENST00000643187.1 ) PIK3CA p.Glu545Lys (p.E545K) ( ENST00000263967.4, ENST00000643187.1 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| Knockdown of PTEN in trastuzumab sensitive HER2 br... | PTEN |
PTEN DELETION ( ENST00000371953.8 ) PTEN DELETION ( ENST00000371953.8 ) |
Sensitivity | true | CIViC Evidence | detail |
| ToGA, a Phase III study (NCT01041404) addressed us... | ERBB2 |
ERBB2 AMPLIFICATION ( ENST00000269571.10 ) ERBB2 AMPLIFICATION ( ENST00000269571.10 ) |
Sensitivity | true | CIViC Evidence | detail |
| Tumor xenografts in mice were established with the... | PIK3CA |
PIK3CA p.His1047Arg (p.H1047R) ( ENST00000263967.4, ENST00000643187.1 ) PIK3CA p.His1047Arg (p.H1047R) ( ENST00000263967.4, ENST00000643187.1 ) |
Sensitivity | true | CIViC Evidence | detail |
| In a panel of 47 breast cancer cell lines, HER2 ov... | ERBB2 |
ERBB2 AMPLIFICATION ( ENST00000269571.10 ) ERBB2 AMPLIFICATION ( ENST00000269571.10 ) |
Sensitivity | true | CIViC Evidence | detail |
| Phase 2 study in 27 patients with HER2 positive (I... | ERBB2 |
ERBB2 AMPLIFICATION ( ENST00000269571.10 ) ERBB2 AMPLIFICATION ( ENST00000269571.10 ) |
Sensitivity | true | CIViC Evidence | detail |
| A 71-year old male with metastatic extramammary Pa... | ERBB2 |
ERBB2 AMPLIFICATION ( ENST00000269571.10 ) ERBB2 AMPLIFICATION ( ENST00000269571.10 ) |
Sensitivity | true | CIViC Evidence | detail |
| In a retrospective study of 111 HER2-positive meta... | PTEN |
PTEN DELETION ( ENST00000371953.8 ) PTEN DELETION ( ENST00000371953.8 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In a retrospective study of 182 metastatic breast ... | PTEN |
PTEN DELETION ( ENST00000371953.8 ) PTEN DELETION ( ENST00000371953.8 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In retrospective study of 175 metastatic breast ca... | PIK3CA | PIK3CA MUTATION PIK3CA MUTATION | Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In a retrospective study of 105 HER2-positive meta... | PIK3CA | PIK3CA MUTATION PIK3CA MUTATION | Resitance or Non-Reponse | true | CIViC Evidence | detail |
| Breast cancer cell lines with oncogenic PIK3CA mut... | PIK3CA |
PIK3CA p.His1047Arg (p.H1047R) ( ENST00000263967.4, ENST00000643187.1 ) PIK3CA p.His1047Arg (p.H1047R) ( ENST00000263967.4, ENST00000643187.1 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| Patient was a 35 year old male who was treated wit... | ERBB2 |
ERBB2 p.Leu755Ser (p.L755S) ( ENST00000269571.10, ENST00000406381.6, ENST00000445658.6, ENST00000541774.5, ENST00000584450.5, ENST00000584601.5 ) ERBB2 p.Leu755Ser (p.L755S) ( ENST00000269571.10, ENST00000406381.6, ENST00000445658.6, ENST00000541774.5, ENST00000584450.5, ENST00000584601.5 ) |
Sensitivity | false | CIViC Evidence | detail |
| A randomized clinical trial of 469 patients with p... | ERBB2 |
ERBB2 AMPLIFICATION ( ENST00000269571.10 ) ERBB2 AMPLIFICATION ( ENST00000269571.10 ) |
Sensitivity | true | CIViC Evidence | detail |
| A randomized clinical trial of 186 patients with p... | ERBB2 |
ERBB2 AMPLIFICATION ( ENST00000269571.10 ) ERBB2 AMPLIFICATION ( ENST00000269571.10 ) |
Sensitivity | true | CIViC Evidence | detail |
| This is Phase II trial of Trastuzumab and capecita... | ERBB2 | ERBB2 OVEREXPRESSION ERBB2 OVEREXPRESSION | Sensitivity | false | CIViC Evidence | detail |
| Patients with metastatic pancreatic cancer with IH... | ERBB2 | ERBB2 OVEREXPRESSION ERBB2 OVEREXPRESSION | Sensitivity | false | CIViC Evidence | detail |
| The phase 2a MyPathway study assigned patients wit... | ERBB2 | ERBB2 MUTATION ERBB2 MUTATION | Sensitivity | true | CIViC Evidence | detail |
| The phase 2a MyPathway study assigned patients wit... | ERBB2 |
ERBB2 AMPLIFICATION ( ENST00000269571.10 ) ERBB2 AMPLIFICATION ( ENST00000269571.10 ) |
Sensitivity | true | CIViC Evidence | detail |
| The phase 2a MyPathway study assigned patients wit... | ERBB2 |
ERBB2 AMPLIFICATION ( ENST00000269571.10 ) ERBB2 AMPLIFICATION ( ENST00000269571.10 ) |
Sensitivity | true | CIViC Evidence | detail |
| The phase 2a MyPathway study assigned patients wit... | ERBB2 |
ERBB2 AMPLIFICATION ( ENST00000269571.10 ) ERBB2 AMPLIFICATION ( ENST00000269571.10 ) |
Sensitivity | true | CIViC Evidence | detail |
| The phase 2a MyPathway study assigned patients wit... | ERBB2 |
ERBB2 AMPLIFICATION ( ENST00000269571.10 ) ERBB2 AMPLIFICATION ( ENST00000269571.10 ) |
Sensitivity | true | CIViC Evidence | detail |
| The phase 2a MyPathway study assigned patients wit... | ERBB2 |
ERBB2 AMPLIFICATION ( ENST00000269571.10 ) ERBB2 AMPLIFICATION ( ENST00000269571.10 ) |
Sensitivity | true | CIViC Evidence | detail |
| The phase 2a MyPathway study assigned patients wit... | ERBB2 |
ERBB2 AMPLIFICATION ( ENST00000269571.10 ) ERBB2 AMPLIFICATION ( ENST00000269571.10 ) |
Sensitivity | false | CIViC Evidence | detail |
| Case report of a 61-year-old caucasian male with a... | ERBB2 | ERBB2 OVEREXPRESSION ERBB2 OVEREXPRESSION | Sensitivity | true | CIViC Evidence | detail |
| Case report of a a 58 year old man with multiple b... | ERBB2 | ERBB2 OVEREXPRESSION ERBB2 OVEREXPRESSION | Sensitivity | true | CIViC Evidence | detail |
| PTEN loss is associated with loss of sensitivity t... | PTEN |
PTEN DELETION ( ENST00000371953.8 ) PTEN DELETION ( ENST00000371953.8 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In HER2+ metastatic breast cancer treated with tra... | AKT2 | AKT2 EXPRESSION AKT2 EXPRESSION | Sensitivity | true | CIViC Evidence | detail |
| In update report of a phase 2 trial, Patients with... | ERBB2 |
ERBB2 AMPLIFICATION ( ENST00000269571.10 ) ERBB2 AMPLIFICATION ( ENST00000269571.10 ) |
Sensitivity | true | CIViC Evidence | detail |
| A patient with cholangiocarcinoma harboring with E... | ERBB2 |
ERBB2 AMPLIFICATION ( ENST00000269571.10 ) ERBB2 AMPLIFICATION ( ENST00000269571.10 ) |
Sensitivity | true | CIViC Evidence | detail |
| In 48 patients with advanced gastric cancer, retro... | PTEN |
PTEN DELETION ( ENST00000371953.8 ) PTEN DELETION ( ENST00000371953.8 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| HER4 nuclear translocation was identified as a med... | ERBB4 | ERBB4 NUCLEAR TRANSLOCATION ERBB4 NUCLEAR TRANSLOCATION | Resitance or Non-Reponse | true | CIViC Evidence | detail |
| siRNA knockdown of HER4 or inhibition with neratin... | ERBB4 | ERBB4 EXPRESSION ERBB4 EXPRESSION | Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In this phase 2 trial, treatment-naive, ERBB2-posi... | ERBB2 |
ERBB2 AMPLIFICATION ( ENST00000269571.10 ) ERBB2 AMPLIFICATION ( ENST00000269571.10 ) |
Sensitivity | true | CIViC Evidence | detail |
| Trastuzumab was more effective in cell lines (SKBR... | PTEN | PTEN EXPRESSION PTEN EXPRESSION | Sensitivity | true | CIViC Evidence | detail |
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT01104571 | Active, not recruiting | Phase 3 | Trastuzumab or Lapatinib Ditosylate in Treating Women With Early Breast Cancer | April 2010 | September 2025 |
| NCT05207722 | Active, not recruiting | Phase 1/Phase 2 | CYNK-101 in Combination With Trastuzumab and Pembrolizumab in Patients With Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma | April 14, 2022 | February 15, 2025 |
| NCT03095352 | Active, not recruiting | Phase 2 | Pembrolizumab With Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients With Chest Wall Disease | September 2, 2017 | October 31, 2024 |
| NCT03013218 | Active, not recruiting | Phase 1 | A Study of Evorpacept (ALX148) in Patients With Advanced Solid Tumors and Lymphoma (ASPEN-01) | February 3, 2017 | December 1, 2024 |
| NCT04579380 | Active, not recruiting | Phase 2 | Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations | January 11, 2021 | May 31, 2025 |
| NCT00769379 | Active, not recruiting | Phase 3 | Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy | November 10, 2008 | March 7, 2025 |
| NCT03006172 | Active, not recruiting | Phase 1 | To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer | December 13, 2016 | November 30, 2024 |
| NCT02947685 | Active, not recruiting | Phase 3 | Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer | June 21, 2017 | July 31, 2026 |
| NCT01191697 | Active, not recruiting | Phase 2 | CAPOX, Bevacizumab and Trastuzumab for Patients With HER2-Positive Metastatic Esophagogastric Cancer | February 2011 | July 2024 |
| NCT04285671 | Active, not recruiting | Phase 1/Phase 2 | Necitumumab and Trastuzumab in Combination With Osimertinib for the Treatment of Refractory Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV Non-small Cell Lung Cancer | January 29, 2021 | December 2, 2026 |
| NCT02827877 | Active, not recruiting | Phase 2 | Cu64-DOTA-trastuzumab PET and Markers Predicting Response to Neoadjuvant Trastuzumab + Pertuzum in HER2+ Breast Cancer | July 15, 2016 | December 30, 2024 |
| NCT02654119 | Active, not recruiting | Phase 2 | Cyclophosphamide, Paclitaxel, and Trastuzumab in Treating Stage I-II HER2/Neu Positive Breast Cancer After Surgery | December 11, 2015 | November 20, 2026 |
| NCT00770809 | Active, not recruiting | Phase 3 | Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by Surgery | December 1, 2008 | July 10, 2024 |
| NCT03414658 | Active, not recruiting | Phase 2 | The AVIATOR Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanced HER2+ Breast Cancer | June 21, 2018 | May 31, 2025 |
| NCT02625441 | Active, not recruiting | Phase 3 | Adjuvant Trastuzumab, Pertuzumab Plus Docetaxel in the Treatment of Early HER2-positive Breast Cancer | December 2015 | June 2025 |
| NCT06136897 | Active, not recruiting | Phase 2 | Testing Trastuzumab and Pertuzumab in Patients With Higher Than Normal Copies of the HER2 Gene Found in Their Tumors (MATCH - Subprotocol J) | March 13, 2017 | June 24, 2024 |
| NCT01273610 | Active, not recruiting | Phase 2 | Tolerability of the Combination of Lapatinib and Trastuzumab in Adults Age 60 or Older With HER2 Positive Locally Advanced or Metastatic Breast Cancer | April 20, 2011 | February 22, 2025 |
| NCT01275677 | Active, not recruiting | Phase 3 | Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer | January 6, 2011 | July 12, 2024 |
| NCT04784715 | Active, not recruiting | Phase 3 | Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09) | April 26, 2021 | December 30, 2029 |
| NCT05426486 | Active, not recruiting | Phase 2/Phase 3 | A Study of ARX788 Combined With Pyrotinib Maleate Versus TCBHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients | May 23, 2022 | December 30, 2028 |
| NCT04082364 | Active, not recruiting | Phase 2/Phase 3 | Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer | September 30, 2019 | June 2025 |
| NCT03379428 | Active, not recruiting | Phase 1/Phase 2 | Trial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast Cancer | November 29, 2017 | June 2024 |
| NCT03365882 | Active, not recruiting | Phase 2 | S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery | November 27, 2017 | November 20, 2024 |
| NCT05555251 | Active, not recruiting | Phase 1/Phase 2 | BI-1607 in Combination With Trastuzumab in Subjects With HER2-positive Advanced Solid Tumors | July 28, 2022 | April 2024 |
| NCT04499924 | Active, not recruiting | Phase 2/Phase 3 | Tucatinib, Trastuzumab, Ramucirumab, and Paclitaxel Versus Paclitaxel and Ramucirumab in Previously Treated HER2+ Gastroesophageal Cancer | March 22, 2021 | March 31, 2027 |
| NCT03747120 | Active, not recruiting | Phase 2 | Neoadjuvant Her2-targeted Therapy and Immunotherapy With Pembrolizumab | January 25, 2019 | July 2025 |
| NCT01358877 | Active, not recruiting | Phase 3 | A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer | November 8, 2011 | November 28, 2024 |
| NCT03304080 | Active, not recruiting | Phase 1/Phase 2 | Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in HR-positive, HER2-positive Metastatic Breast | December 20, 2017 | December 2024 |
| NCT04307329 | Active, not recruiting | Phase 2 | Monalizumab and Trastuzumab In Metastatic HER2-pOSitive breAst Cancer: MIMOSA-trial | March 23, 2021 | May 1, 2030 |
| NCT04262804 | Active, not recruiting | Phase 2 | A Study to Evaluate the Efficacy and Safety of Margetuximab Plus Chemotherapy in the Treatment of Chinese Patients With HER2+ MBC | January 13, 2020 | December 2023 |
| NCT04158258 | Active, not recruiting | A Study to Describe the Diagnosis, Anti-Cancer Treatment and Clinical Outcome in Patients With Newly Diagnosed Breast Cancer in Latin America | February 21, 2020 | November 28, 2025 | |
| NCT02578368 | Active, not recruiting | Phase 3 | Chemotherapy Alone vs. Chemotherapy + Surgical Resection in Patients With Limited-metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction | February 2016 | February 2026 |
| NCT03738553 | Active, not recruiting | Multiparametric MRI for Assessing Breast Cancer Response to Anti-HER2 Therapy | August 2013 | September 2025 | |
| NCT02465060 | Active, not recruiting | Phase 2 | Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) | August 17, 2015 | December 31, 2025 |
| NCT04208178 | Active, not recruiting | Phase 3 | Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation | July 16, 2020 | September 16, 2024 |
| NCT02436993 | Active, not recruiting | Phase 2 | Phase II Breast Ca Carboplatin + Paclitaxel With Pertuzumab + Trastuzumab or Bevacizumab | April 2015 | June 2024 |
| NCT02390427 | Active, not recruiting | Phase 1 | Phase Ib Dose-escalation Trial of Taselisib (GDC-0032) in Combination With Anti-HER2 Therapies in Participants With Advanced HER2+ Breast Cancer | April 20, 2015 | May 2024 |
| NCT03199885 | Active, not recruiting | Phase 3 | Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer | April 5, 2019 | May 15, 2025 |
| NCT03716180 | Active, not recruiting | Phase 1 | DAPHNe: Paclitaxel/Trastuzumab/Pertuzumab in HER2-Positive BC | November 5, 2018 | September 1, 2030 |
| NCT02344472 | Active, not recruiting | Phase 3 | Detect V / CHEVENDO (Chemo vs. Endo) | September 2015 | January 31, 2025 |
| NCT05113251 | Active, not recruiting | Phase 3 | Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer | October 25, 2021 | April 30, 2027 |
| NCT04721977 | Active, not recruiting | Phase 2 | A Study of Tucatinib (MK-7119) in Combination With Trastuzumab and Capecitabine in Participants With Previously Treated Locally Advanced Unresectable or Metastatic Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Breast Carcinoma (MK-7119-001) | April 8, 2021 | December 6, 2028 |
| NCT00295893 | Active, not recruiting | Phase 2 | Combination Chemotherapy With or Without Trastuzumab in Treating Patients With Stage II or Stage III Breast Cancer | September 27, 2005 | December 15, 2024 |
| NCT05063786 | Active, not recruiting | Phase 3 | Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in Patients With PIK3CA Mutated Previously Treated HER2+ Advanced BrEasT Cancer (ALPHABET) | September 14, 2021 | November 2024 |
| NCT02339532 | Active, not recruiting | Phase 2 | Neoadjuvant Phase II Trial in Patients With T1c Operable, HER2-positive Breast Cancer According to TOP2A Status | January 2015 | June 2024 |
| NCT05574881 | Active, not recruiting | Phase 1/Phase 2 | Dalpiciclib, Fulvestrant, Trastuzumab and Pertuzumab in HR Positive, HER2 Positive Metastatic Breast Cancer | September 1, 2022 | January 1, 2025 |
| NCT03615326 | Active, not recruiting | Phase 3 | Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811) | October 5, 2018 | December 30, 2024 |
| NCT02320435 | Active, not recruiting | Phase 3 | A Safety and Efficacy Extension Study of Pertuzumab in Patients With Solid Tumors Previously Enrolled in a Hoffmann-La Roche-Sponsored Pertuzumab Clinical Trial | February 2, 2015 | December 31, 2025 |
| NCT04908813 | Active, not recruiting | Phase 2 | Study of HLX22 in Combanition With Trastuzumab and Chemotherapy Versus Placebo in Combination With Trastuzumab and Chemotherapy for Treatment of Locally Advanced or Metastatic Gastric Cancer | September 29, 2021 | December 2025 |
| NCT05504720 | Active, not recruiting | Phase 2 | Evaluating Pembrolizumab, Trastuzumab and FLOT as Perioperative Treatment of HER2-positive, Localized Esophagogastric Adenocarcinoma | February 13, 2023 | December 2027 |
| NCT04188548 | Active, not recruiting | Phase 1 | A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer | December 10, 2019 | December 2027 |
| NCT03595592 | Active, not recruiting | Phase 3 | Neoadjuvant Treatment of HER2 Positive Early High-risk and Locally Advanced Breast Cancer | September 7, 2018 | March 15, 2027 |
| NCT02252887 | Active, not recruiting | Phase 2 | Gemcitabine, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer After Prior Trastuzumab/Pertuzumab, or Pertuzumab Based Therapy | January 12, 2015 | September 2024 |
| NCT03179904 | Active, not recruiting | Phase 2 | TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer | August 3, 2017 | July 30, 2024 |
| NCT03523585 | Active, not recruiting | Phase 3 | DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02] | August 1, 2018 | May 1, 2025 |
| NCT03125928 | Active, not recruiting | Phase 2 | Clinical Trial of Atezolizumab With Paclitaxel, Trastuzumab, and Pertuzumab in Patients With Metastatic HER-2 Positive Breast Cancer | June 13, 2017 | December 2024 |
| NCT02226276 | Active, not recruiting | N/A | Copper Cu 64-DOTA-Trastuzumab PET in Predicting Response to Treatment With Ado-Trastuzumab Emtansine in Patients With Metastatic HER2 Positive Breast Cancer | January 7, 2015 | December 7, 2024 |
| NCT04661150 | Active, not recruiting | Phase 2 | A Study of Atezolizumab and Trastuzumab in Combination With Capecitabine and Oxaliplatin in Patients With HER2 Positive Locally Advanced Resectable Gastric Cancer of Adenocarcinoma of Gastroesophageal Junction | March 12, 2021 | August 30, 2026 |
| NCT02205047 | Active, not recruiting | Phase 2 | Neoadjuvant Study Using Trastuzumab or Trastuzumab With Pertuzumab in Gastric or Gastroesophageal Junction Adenocarcinoma | July 15, 2015 | December 31, 2028 |
| NCT02057133 | Active, not recruiting | Phase 1 | A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread | March 10, 2014 | December 31, 2024 |
| NCT01730833 | Active, not recruiting | Phase 2 | Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Advanced Breast Cancer | July 17, 2013 | December 31, 2024 |
| NCT01745965 | Active, not recruiting | Phase 2 | A Prospective, Randomized Multicenter, Open-label Comparison of Preoperative Trastuzumab Emtansine (T-DM1) With or Without Standard Endocrine Therapy vs. Trastuzumab With Standard Endocrine Therapy Given for Twelve Weeks in Patients With Operable HER2+/HR+ Breast Cancer Within the ADAPT Protocol. | November 2012 | October 2024 |
| NCT03101748 | Active, not recruiting | Phase 1/Phase 2 | Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer | January 29, 2018 | January 1, 2026 |
| NCT03501979 | Active, not recruiting | Phase 2 | Tucatinib, Trastuzumab, and Capecitabine for the Treatment of HER2+ LMD | February 20, 2019 | July 22, 2024 |
| NCT01750073 | Active, not recruiting | Phase 2 | Paclitaxel & Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Previously Untreated Breast Cancer | December 7, 2012 | June 2026 |
| NCT04425018 | Active, not recruiting | Phase 2 | MARGetuximab Or Trastuzumab (MARGOT) | July 13, 2020 | July 1, 2027 |
| NCT01772472 | Active, not recruiting | Phase 3 | A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE) | April 3, 2013 | May 15, 2024 |
| NCT00999804 | Active, not recruiting | Phase 2 | Extension Study of Lapatinib Plus Herceptin With or Without Endocrine Therapy | October 2011 | January 2024 |
| NCT02003209 | Active, not recruiting | Phase 3 | Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer | January 15, 2014 | December 31, 2024 |
| NCT01937117 | Active, not recruiting | Phase 2 | Pertuzumab and Trastuzumab as Neoadjuvant Treatment in Patients With HER2-Positive Breast Cancer | January 30, 2014 | May 2025 |
| NCT01897441 | Active, not recruiting | N/A | Chemotherapy Before Surgery and Tissue Sample Collection in Patients With Stage IIA-IIIC Breast Cancer | June 2013 | December 2026 |
| NCT01796197 | Active, not recruiting | Phase 2 | Paclitaxel + Trastuzumab + Pertuzumab as Pre-Op for Inflammatory BrCa | August 2013 | July 2024 |
| NCT04398914 | Active, not recruiting | Phase 2 | Pyrotinib, Trastuzumab, Pertuzumab and Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer | May 30, 2020 | December 30, 2027 |
| NCT04172259 | Active, not recruiting | Phase 2 | ACHP-THP vs EC-THP as Neoadjuvant Therapy for HER2-positive EBC | January 10, 2019 | September 30, 2026 |
| NCT01853748 | Active, not recruiting | Phase 2 | T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial) | May 2013 | May 2024 |
| NCT03448042 | Active, not recruiting | Phase 1 | A Study of Runimotamab in Participants With Locally Advanced or Metastatic HER2-Expressing Cancers | June 6, 2018 | May 31, 2025 |
| NCT00431704 | Active, not recruiting | Phase 2 | VinCaT: Vinorelbine, Carboplatin and Trastuzumab in Advanced Her-2 Positive Breast Cancer | October 2007 | December 2023 |
| NCT04591431 | Active, not recruiting | Phase 2 | The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy | October 7, 2020 | June 2025 |
| NCT03417544 | Active, not recruiting | Phase 2 | Atezolizumab + Pertuzumab + Trastuzumab In CNS Mets In BC | May 21, 2018 | December 2025 |
| NCT04220203 | Approved for marketing | Treatment Protocol of Tucatinib With Capecitabine and Trastuzumab in Patients With Unresectable Previously Treated HER2+ Breast Cancer | |||
| NCT00364611 | Completed | Phase 2 | Pilot Study of Docetaxel & Bevacizumab +/- Trastuzumab in First-Line Treatment of Patients With Metastatic Breast Cancer | August 2006 | April 2012 |
| NCT00367471 | Completed | Phase 1 | Combination Of Lapatinib With Carboplatin, Paclitaxel, and With or Without Trastuzumab In Metastatic Breast Cancer. | December 7, 2006 | September 12, 2019 |
| NCT00379015 | Completed | Phase 2 | Epirubicin and Cyclophosphamide Followed By Docetaxel and Trastuzumab in Treating Women With HER2-Positive Stage III or Stage IV Breast Cancer | January 2006 | March 2016 |
| NCT00381901 | Completed | Phase 3 | Trastuzumab for 6 Months or 1 Year in Treating Women With Nonmetastatic Breast Cancer That Can Be Removed By Surgery | May 2006 | |
| NCT00386685 | Completed | Phase 2 | XRP9881 in Combination With Trastuzumab in Metastatic Breast Cancer | July 2006 | January 2011 |
| NCT00387907 | Completed | Phase 2 | Study of Larotaxel in Combination With Weekly Herceptin® in Patients With HER2 Positive Metastatic Breast Cancer | October 2006 | March 2008 |
| NCT00392392 | Completed | Phase 2 | Preoperative Bevacizumab and Trastuzumab With ABI-007 and Carboplatin in HER2+ Breast Cancer | October 2006 | December 2011 |
| NCT00398567 | Completed | Phase 1/Phase 2 | A Phase 1/2 Study Of HKI-272 (Neratinib) in Combination With Trastuzumab (Herceptin) In Subjects With Advanced Breast Cancer | April 4, 2007 | March 2, 2018 |
| NCT00399529 | Completed | Phase 2 | Trastuzumab, Cyclophosphamide, and an Allogeneic GM-CSF-secreting Breast Tumor Vaccine for the Treatment of HER-2/Neu-Overexpressing Metastatic Breast Cancer | September 2006 | February 2010 |
| NCT00401427 | Completed | Phase 2 | HERVIN: Trastuzumab and Vinorelbine in Metastatic Breast Cancer | November 2002 | December 2006 |
| NCT00404066 | Completed | Phase 2 | Phase 2 Neoadjuvant Doxorubicin and Cyclophosphamide -> Docetaxel With Lapatinib in Stage II/III Her2Neu+ Breast Cancer | October 2006 | March 2011 |
| NCT00407888 | Completed | Phase 2 | Doxorubicin Hydrochloride, Cyclophosphamide, and Filgrastim Followed By Paclitaxel Albumin-Stabilized Nanoparticle Formulation With or Without Trastuzumab in Treating Patients With Breast Cancer Previously Treated With Surgery | May 2006 | July 2012 |
| NCT00411788 | Completed | Phase 2 | A Phase II Study of Rapamycin and Trastuzumab for Patients With HER-2 Receptor Positive Metastatic Breast Cancer | December 2006 | May 2010 |
| NCT00426556 | Completed | Phase 1 | Efficacy and Safety of Everolimus in Combination Therapy, in Patients With HER2-overexpressing Metastatic Breast Cancer | July 2007 | March 2014 |
| NCT00428922 | Completed | Phase 2 | Trastuzumab (Herceptin), Bevacizumab, and Docetaxel (Taxotere) Trial in Stage IV Metastatic Breast Cancer (MBC) Patients | June 14, 2007 | February 7, 2017 |
| NCT00429247 | Completed | Phase 2 | Randomized Trial With Trastuzumab Versus Observation in Breast Cancer Patients | February 2003 | December 2007 |
| NCT00429299 | Completed | Phase 2 | Neoadjuvant Study With Chemotherapy, Lapatinib And Trastuzumab In Breast Cancer | August 2006 | June 2012 |
| NCT00433407 | Completed | N/A | T-Cell Response in Patients Receiving Trastuzumab and/or Chemotherapy for HER2-Positive Solid Tumors | August 2005 | |
| NCT00436566 | Completed | Phase 2 | Doxorubicin and Cyclophosphamide Followed By Trastuzumab, Paclitaxel, and Lapatinib in Treating Patients With Early-Stage HER2-Positive Breast Cancer That Has Been Removed By Surgery | March 16, 2007 | July 22, 2019 |
| NCT00446030 | Completed | Phase 2 | Pilot Study of the Safety & Efficacy of Two Docetaxel-Based Regimens Plus Bevacizumab for the Adjuvant Treatment of Subjects With Node Positive or High Risk Node Negative Breast Cancer | March 2007 | August 2010 |
| NCT00448279 | Completed | Phase 3 | THOR Study: A Study of Continued Herceptin (Trastuzumab) in Combination With Second Line Chemotherapy in Patients With HER2 Positive Metastatic Breast Cancer. | April 2007 | September 2010 |
| NCT00458237 | Completed | Phase 1/Phase 2 | Dose Escalation Followed by Study of RAD001 in Combination With Trastuzumab in HER2-Positive Metastatic Breast Cancer | April 2007 | April 2010 |
| NCT00464646 | Completed | Phase 2 | Therapy With Bevacizumab (BEV), Epirubicin, and Cyclophosphamide Followed by Docetaxel Plus Trastuzumab and BEV Given as Neoadjuvant or Adjuvant Therapy for Women With Locally Advanced HER2 Positive Invasive Breast Cancer | May 2007 | May 2014 |
| NCT00475670 | Completed | Phase 2 | A Study of Herceptin (Trastuzumab) in Women With Metastatic Breast Cancer | October 2005 | June 2012 |
| NCT00482391 | Completed | Phase 2 | Doxorubicin and Cyclophosphamide Followed by Paclitaxel, Trastuzumab, and Lapatinib in Treating Patients With HER2/Neu-Overexpressed Breast Cancer | March 2007 | July 2011 |
| NCT00485979 | Completed | Phase 2 | Treatment of Larotaxel/Docetaxel, +/- Trastuzumab, After Anthracycline-cyclophosphamide in Breast Cancer Patients | June 2007 | August 2010 |
| NCT00490139 | Completed | Phase 3 | ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D | May 16, 2007 | July 1, 2021 |
| NCT00490646 | Completed | Phase 2 | A Phase II Combination of Trastuzumab and Ixabepilone Versus Trastuzumab and Docetaxel in Patients With Advanced and/or Metastatic Breast Cancer | February 2008 | November 2011 |
| NCT00513292 | Completed | Phase 3 | Combination Chemotherapy and Paclitaxel Plus Trastuzumab in Treating Women With Palpable Breast Cancer That Can Be Removed by Surgery | July 2007 | February 21, 2013 |
| NCT00524303 | Completed | Phase 2 | Lapatinib +/- Trastuzumab In Addition To Standard Neoadjuvant Breast Cancer Therapy. | August 2007 | August 2015 |
| NCT00542451 | Completed | Phase 2 | Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer | October 2007 | August 30, 2022 |
| NCT00543504 | Completed | Phase 1 | Bevacizumab in Multiple Phase I Combinations | October 10, 2007 | April 29, 2020 |
| NCT00548184 | Completed | Phase 2 | Lapatinib and Trastuzumab With or Without Endocrine Therapy | May 2008 | January 2014 |
| NCT00553358 | Completed | Phase 3 | Neo ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) Study | January 5, 2008 | December 23, 2019 |
| NCT00567190 | Completed | Phase 3 | A Study to Evaluate Pertuzumab + Trastuzumab + Docetaxel vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-Positive Metastatic Breast Cancer | February 12, 2008 | November 23, 2018 |
| NCT00574587 | Completed | Phase 1/Phase 2 | Trial for Locally Advanced Breast Cancer Using Vorinostat Plus Chemotherapy | December 2007 | May 2014 |
| NCT00615602 | Completed | Phase 3 | Six vs 12 Months of Trastuzumab With Docetaxel Following FEC as Adjuvant Treatment in N+ Breast Cancer | October 2004 | May 2012 |
| NCT00618657 | Completed | Phase 2 | Carboplatin+Nab-paclitaxel, Plus Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting | February 2008 | July 2021 |
| NCT00629499 | Completed | Phase 2 | Nanoparticle Albumin-Bound (Nab) Paclitaxel/Cyclophosphamide in Early-Stage Breast Cancer | April 2008 | September 2010 |
| NCT00639366 | Completed | Phase 3 | Radiation Therapy to the Head in Preventing Brain Metastases in Women Receiving Trastuzumab and Chemotherapy for Metastatic or Locally Advanced Breast Cancer | February 2007 | October 2010 |
| NCT00667251 | Completed | Phase 3 | Chemotherapy and Lapatinib or Trastuzumab in Treating Women With HER2/Neu-Positive Metastatic Breast Cancer | October 7, 2008 | July 27, 2022 |
| NCT00670982 | Completed | Phase 2 | Bevacizumab in Combination With Vinorelbine and Trastuzumab for HER2-Positive, Metastatic Breast Cancer | May 2008 | December 2012 |
| NCT00679341 | Completed | Phase 2 | A Study of the Efficacy and Safety of Trastuzumab Emtansine (Trastuzumab-MCC-DM1) vs. Trastuzumab (Herceptin®) and Docetaxel (Taxotere®) in Patients With Metastatic HER2-positive Breast Cancer Who Have Not Received Prior Chemotherapy for Metastatic Disease | September 2008 | May 2012 |
| NCT00687440 | Completed | Phase 2 | A Study to Determine the Activity of Caelyx With Trastuzumab and Docetaxel in the Treatment of Metastatic Breast Cancer (Study P03679) | July 15, 2005 | October 24, 2008 |
| NCT00712881 | Completed | Phase 2 | Combination Therapy With MYOCET® (Doxorubicin HCL Liposome for Injection) in Participants With HER2-Positive Breast Cancer | October 13, 2008 | September 17, 2015 |
| NCT00736970 | Completed | Phase 2 | Oral Deforolimus With Trastuzumab for Patients With HER2-positive Trastuzumab-Refractory Metastatic Breast Cancer (8669-009) | July 2008 | May 2011 |
| NCT00755313 | Completed | Effects of Chemotherapy on the Brain in Women With Newly Diagnosed Early-Stage Breast Cancer | May 2007 | June 6, 2014 | |
| NCT00769470 | Completed | Phase 2 | Docetaxel, Carboplatin, and Trastuzumab and/or Lapatinib in Treating Women With Stage I, Stage II, or Stage III Breast Cancer That Can Be Removed by Surgery | April 2009 | |
| NCT00788931 | Completed | Phase 1 | A Trial l of Panobinostat Given in Combination With Trastuzumab and Paclitaxel in Adult Female Patients With HER2 Positive Metastatic Breast Cancer | December 2008 | |
| NCT00795678 | Completed | Chemotherapeutic Agents in Brain/Breast | September 2008 | April 2013 | |
| NCT00796978 | Completed | Phase 2 | Trastuzumab in Treating Older Women With Early-Stage Breast Cancer | February 5, 2009 | February 26, 2020 |
| NCT00803556 | Completed | Phase 1 | Clinical Trial of the Combination of Intravenous Alvespimycin (KOS-1022), Trastuzumab With or Without Paclitaxel in Patients With Advanced Solid Tumor Malignancies or Her2 Positive Metastatic Breast Cancer Who Have Previously Failed Trastuzumab Therapy | January 2006 | August 2009 |
| NCT00820222 | Completed | Phase 3 | Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer | April 14, 2009 | March 22, 2018 |
| NCT00820872 | Completed | Phase 2 | Docetaxel, Carboplatin, Trastuzumab, and Lapatinib in Treating Patients With Early Stage Breast Cancer | February 2009 | August 15, 2019 |
| NCT00821886 | Completed | Phase 2 | Neoadjuvant Ixabepilone/Carboplatin/Trastuzumab in HER2-Positive Locally Advanced Breast Cancer | February 2009 | October 2014 |
| NCT00826267 | Completed | Phase 2 | 6 Weeks Treatment of Locally Advanced Breast Cancer With BIBW 2992 (Afatinib) or Lapatinib or Trastuzumab | January 2009 | |
| NCT00833963 | Completed | A Study of Pregnancy and Pregnancy Outcomes in Women With Breast Cancer Treated With Trastuzumab, Pertuzumab in Combination With Trastuzumab, or Ado-Trastuzumab Emtansine | January 14, 2009 | April 13, 2017 | |
| NCT00841828 | Completed | Phase 2 | Trastuzumab Versus Lapatinib as Neoadjuvant Treatment for Her2+ Patients | February 2009 | December 2013 |
| NCT00847171 | Completed | Phase 2 | Trastuzumab, Cyclophosphamide, and Vaccine Therapy in Treating Patients With High-Risk or Metastatic Breast Cancer | December 2008 | June 2013 |
| NCT00847366 | Completed | N/A | Open Label Trial of Perifosine in Patients Currently Being Treated on Perifosine Trials in Solid Tumors or Multiple Myeloma | May 2008 | December 2012 |
| NCT00875238 | Completed | Side Effects Involving the Heart in Women With Breast Cancer Receiving Doxorubicin and Trastuzumab | June 2008 | March 2015 | |
| NCT00876395 | Completed | Phase 3 | Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer | September 10, 2009 | October 23, 2017 |
| NCT00896376 | Completed | N/A | Trastuzumab in Treating Women With Metastatic Breast Cancer | December 2005 | September 2010 |
| NCT00912340 | Completed | Phase 2 | Phase II Trial of EVEROLIMUS ± Trastuzumab in Hormone-Refractory Metastatic Breast Cancer | May 2009 | July 2017 |
| NCT00915018 | Completed | Phase 2 | Study Evaluating Neratinib Plus Paclitaxel VS Trastuzumab Plus Paclitaxel In ErbB-2 Positive Advanced Breast Cancer | August 21, 2009 | June 28, 2018 |
| NCT00923299 | Completed | Phase 1/Phase 2 | Cetuximab and Trastuzumab in Treating Patients With Metastatic Pancreatic Cancer That Progressed After Previous Treatment With Gemcitabine | December 2008 | March 2011 |
| NCT00927589 | Completed | Phase 1 | A Study to Evaluate Corrected QT Interval and Drug-Drug Interaction of Trastuzumab on Carboplatin in the Presence of Docetaxel in Patients With HER2-Positive Metastatic or Locally Advanced Inoperable Cancer | July 2009 | February 2013 |
| NCT00928330 | Completed | Phase 1 | Trastuzumab and Trastuzumab-MCC-DM1 Administered Intravenously and GDC-0941 Administered Orally to Patients With HER2-Positive Metastatic Breast Cancer Who Have Progressed on Previous Trastuzumab-Based Therapy | July 2009 | January 2014 |
| NCT00944047 | Completed | Phase 2 | Evaluate Trastuzumab Plus Standard Chemotherapy Given Before Surgery in Breast Cancer Patients With Low HER 2 Expression | July 2009 | August 2017 |
| NCT00949247 | Completed | Early Phase 1 | Docetaxel,Carboplatin,Trastuzumab and Bevacizumab for Breast Cancer and Bone Marrow Micrometastases | December 2009 | January 2013 |
| NCT00950742 | Completed | Phase 1 | Phase I Open Label Trial to Assess Safety of BIBW 2992 (Afatinib) in Combination With Herceptin® in Patients With HER2-positive Advanced Breast Cancer. | August 2009 | October 2013 |
| NCT00960960 | Completed | Phase 1 | A Study of PI3-Kinase Inhibitor GDC-0941 in Combination With Paclitaxel, With and Without Bevacizumab or Trastuzumab, and With Letrozole, in Participants With Locally Recurrent or Metastatic Breast Cancer | August 2009 | December 2015 |
| NCT00968682 | Completed | CADY Study ICORG 08-01 | April 2008 | ||
| NCT00971737 | Completed | Phase 2 | Cyclophosphamide and Vaccine Therapy With or Without Trastuzumab in Treating Patients With Metastatic Breast Cancer | July 2009 | March 2016 |
| NCT00976989 | Completed | Phase 2 | A Study of Pertuzumab in Combination With Herceptin and Chemotherapy in Participants With HER2-Positive Breast Cancer | November 2009 | January 2016 |
| NCT01007942 | Completed | Phase 3 | Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer | October 2009 | June 2015 |
| NCT01008150 | Completed | Phase 2 | Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer | October 2010 | November 25, 2016 |
| NCT01026142 | Completed | Phase 3 | A Study of a Combination of Trastuzumab and Capecitabine With or Without Pertuzumab in Patients With HER2-positive Metastatic Breast Cancer (PHEREXA) | January 26, 2010 | August 7, 2017 |
| NCT01041404 | Completed | Phase 3 | ToGA Study - A Study of Herceptin (Trastuzumab) in Combination With Chemotherapy Compared With Chemotherapy Alone in Patients With HER2-Positive Advanced Gastric Cancer | September 2005 | June 2010 |
| NCT01042925 | Completed | Phase 1/Phase 2 | Study of XL147 (SAR245408) in Combination With Trastuzumab or Paclitaxel and Trastuzumab in Subjects With Metastatic Breast Cancer Who Have Progressed on a Previous Trastuzumab-based Regimen | February 2010 | December 2012 |
| NCT01048099 | Completed | N/A | Use of PRO Onc Assay to Assess HER2 in Patients With Metastatic Breast Cancer | January 2011 | July 2014 |
| NCT01106898 | Completed | Phase 2 | Cyclophosphamide and Paclitaxel With or Without Trastuzumab in Stage I-II Breast Cancer Who Have Undergone Surgery | March 24, 2010 | September 28, 2015 |
| NCT01125566 | Completed | Phase 3 | LUX-Breast 1: BIBW 2992 (Afatinib) in HER2-positive Metastatic Breast Cancer Patients After One Prior Herceptin Treatment | June 22, 2010 | July 6, 2018 |
| NCT01142778 | Completed | Phase 2 | A Study of Bevacizumab Added to Trastuzumab Plus Docetaxel in the Neoadjuvant Setting in Participants With Early Stage HER2-Positive Breast Cancer | May 19, 2010 | December 13, 2017 |
| NCT01160211 | Completed | Phase 3 | A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer | May 5, 2011 | June 6, 2022 |
| NCT01196390 | Completed | Phase 3 | Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer | February 14, 2011 | August 15, 2023 |
| NCT01235897 | Completed | Phase 1 | MK-2206, Paclitaxel and Trastuzumab in Treating Patients With HER2-overexpressing Solid Tumor Malignancies | March 2011 | November 2013 |
| NCT01242449 | Completed | Phase 2 | Oral Vinorelbine in Combination With Trastuzumab for Metastatic Breast Cancer | November 2010 | October 2014 |
| NCT01271920 | Completed | Phase 1/Phase 2 | Combination of AUY922 With Trastuzumab in HER2+ Advanced Breast Cancer Patients Previously Treated With Trastuzumab | September 2010 | October 2013 |
| NCT01295086 | Completed | N/A | Taxotere®, Eloxatin® and Xeloda® (TEX) in Combination With Herceptin® as Treatment for HER2 Positive Non-resectable Cancer | March 2011 | January 2018 |
| NCT01300962 | Completed | Phase 1 | Study of BKM120 or BYL719 and Capecitabine in Patients With Metastatic Breast Cancer | August 2011 | December 31, 2018 |
| NCT01301729 | Completed | Phase 4 | A Study of Herceptin (Trastuzumab) in Combination With a Taxane in Participants With HER2-Positive Breast Cancer Who Relapsed After (Neo)Adjuvant Herceptin Treatment | March 2011 | July 2014 |
| NCT01305941 | Completed | Phase 2 | A Study Of Everolimus, Trastuzumab And Vinorelbine In HER2-Positive Breast Cancer Brain Metastases | September 2011 | October 16, 2017 |
| NCT01306942 | Completed | Phase 1/Phase 2 | Dasatinib In Combination With Trastuzumab And Paclitaxel In First Line Treatment Of Her2-Positive MBC Patients | July 2011 | March 15, 2019 |
| NCT01325207 | Completed | Phase 1/Phase 2 | Intrathecal Trastuzumab for Leptomeningeal Metastases in HER2+ Breast Cancer | August 1, 2011 | January 20, 2019 |
| NCT01340430 | Completed | Phase 2 | Neoadjuvant 5-fluorouracil, Epirubicin and Cyclophosphamide (FEC) Followed by Weekly Paclitaxel and Trastuzumab in Her2 Positive Breast Cancer | March 2011 | January 2022 |
| NCT01351350 | Completed | Phase 1 | Dose Escalation Study of MLN0128 in Combination With Paclitaxel, With/Without Trastuzumab, in Subjects With Advanced Solid Malignancies | February 28, 2011 | September 15, 2017 |
| NCT01367002 | Completed | Phase 2 | Evaluation of Carboplatin/Paclitaxel With and Without Trastuzumab (Herceptin) in Uterine Serous Cancer | June 2011 | June 30, 2022 |
| NCT01373710 | Completed | Phase 1/Phase 2 | Intrathecal Trastuzumab Administration in Metastatic Breast Cancer Patients Developing Carcinomatous Meningitis | May 19, 2011 | April 9, 2018 |
| NCT01384253 | Completed | Phase 1 | Safety Study of ²¹²Pb-TCMC-Trastuzumab Radio Immunotherapy | July 2011 | July 2016 |
| NCT01386580 | Completed | Phase 1/Phase 2 | An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma. | July 2011 | December 2014 |
| NCT01401959 | Completed | Phase 2 | Trial of Eribulin in Patients Who Do Not Achieve Pathologic Complete Response (pCR) Following Neoadjuvant Chemotherapy | September 23, 2011 | April 3, 2017 |
| NCT01423123 | Completed | Phase 1 | Combination of Weekly Paclitaxel With Neratinib and Trastuzumab in Women With Metastatic HER2-positive Breast Cancer | May 2011 | March 2014 |
| NCT01434303 | Completed | Phase 1 | Entinostat, Lapatinib Ditosylate and Trastuzumab in Treating Patients With Locally Recurrent or Distant Relapsed Metastatic Breast Cancer Previously Treated With Trastuzumab Only | January 10, 2012 | February 16, 2016 |
| NCT01461057 | Completed | Phase 2 | A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Patients With HER2-Positive Advanced Gastric Cancer | December 6, 2011 | October 31, 2017 |
| NCT01480583 | Completed | Phase 2 | GRN1005 Alone or in Combination With Trastuzumab in Breast Cancer Patients With Brain Metastases | October 2011 | October 2015 |
| NCT01480674 | Completed | An Observational Study of Patients With HER2-Positive Metastatic or Locally Advanced Breast Cancer Treated With Herceptin (Trastuzumab) in 1st Line and Without Progression For 3 Years | March 28, 2011 | November 16, 2012 | |
| NCT01491737 | Completed | Phase 2 | A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Participants With Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive and Hormone Receptor-Positive Advanced Breast Cancer | February 17, 2012 | November 14, 2019 |
| NCT01503983 | Completed | Phase 2 | Efficacy and Safety of Trastuzumab, Capecitabine y Oxaliplatine as Treatment Gastric Cancer Metastatic (HER2)Positive | August 2011 | May 2015 |
| NCT01526369 | Completed | Phase 3 | A Randomized Study of TH Versus THL in First Line Treatment of HER2-positive Metastatic Breast Cancer | February 13, 2012 | February 17, 2023 |
| NCT01548677 | Completed | Phase 2 | Efficacy Study of Herceptin to Treat HER2-negative CTC Breast Cancer | April 2013 | March 2017 |
| NCT01565083 | Completed | Phase 2 | A Study to Assess Efficacy and Safety of Pertuzumab Given in Combination With Trastuzumab and Vinorelbine in Participants With Metastatic or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer | April 2012 | October 2015 |
| NCT01572038 | Completed | Phase 3 | A Study of Pertuzumab in Combination With Trastuzumab (Herceptin) and a Taxane in First-Line Treatment in Participants With Human Epidermal Growth Factor 2 (HER2)-Positive Advanced Breast Cancer | June 1, 2012 | September 20, 2019 |
| NCT01594177 | Completed | Phase 2 | Dual Blockage With Afatinib and Trastuzumab as Neoadjuvant Treatment for Patients With Locally Advanced or Operable Breast Cancer Receiving Taxane-anthracycline Containing Chemotherapy | May 2012 | March 2014 |
| NCT01602406 | Completed | Phase 1 | Phase I Study LJM716 Combined With Trastuzumab in Patients With HER2 Overexpressing Metastatic Breast or Gastric Cancer | September 21, 2012 | August 2, 2017 |
| NCT01649271 | Completed | Phase 1 | Phase I Trial of Afatinib and Trastuzumab in HER2 Overexpressing Cancer. | July 23, 2012 | June 23, 2016 |
| NCT01670877 | Completed | Phase 2 | Neratinib +/- Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer | December 11, 2012 | March 11, 2021 |
| NCT01674062 | Completed | Phase 2 | A Study of Perjeta (Pertuzumab) in Combination With Herceptin (Trastuzumab) in Participants With Metastatic Breast Cancer | May 2006 | September 2015 |
| NCT01688609 | Completed | Phase 2 | Lapatinib Ditosylate, Trastuzumab, Paclitaxel, and Surgery in Treating Patients With Breast Cancer | July 2012 | August 15, 2016 |
| NCT01746771 | Completed | Phase 1/Phase 2 | A Phase I-II Study of HM781-36B Combined With Paclitaxel and Trastuzumab in HER-2 Positive Advanced Gastric Cancer | November 2012 | August 2015 |
| NCT01748773 | Completed | Phase 2 | A Study of the Combination of Oxaliplatin, Capecitabine, and Trastuzumab With Chemoradiotherapy in the Adjuvant Setting in Operated Participants With Human Epidermal Growth Factor Receptor-2 Positive (HER2+) Gastric or Gastroesophageal Junction Cancer | January 29, 2013 | June 15, 2017 |
| NCT01764022 | Completed | Phase 3 | A Safety and Efficacy Study of BCD-022 With Paclitaxel Compared to Herceptin With Paclitaxel in HER2+ Metastatic Breast Cancer Patients | October 2012 | December 2017 |
| NCT01774786 | Completed | Phase 3 | A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastroesophageal Junction or Gastric Cancer | June 10, 2013 | December 31, 2019 |
| NCT01810393 | Completed | Phase 3 | A Study to Assess Preference for Subcutaneous Trastuzumab Treatment in Participants With Human Epidermal Growth Factor Receptor (HER)2-Positive Metastatic Breast Cancer Responding to First-Line Intravenous Trastuzumab for at Least 3 Years | June 11, 2013 | July 17, 2019 |
| NCT01816594 | Completed | Phase 2 | NeoPHOEBE: Neoadjuvant Trastuzumab + BKM120 in Combination With Weekly Paclitaxel in HER2-positive Primary Breast Cancer | September 3, 2013 | February 18, 2015 |
| NCT01827163 | Completed | Phase 2 | Paclitaxel With Trastuzumab and Lapatinib in HER2-Positive Early Stage Breast Cancer | April 2013 | January 2019 |
| NCT01828736 | Completed | Phase 2 | Efficacy of Combination of Trastuzumab to Gemcitabine - Platinum Advanced or Metastatic Urothelial Carcinoma | February 9, 2004 | February 23, 2010 |
| NCT01835236 | Completed | Phase 2 | Trastuzumab & Pertuzumab Followed by T-DM1 in MBC | March 3, 2013 | May 26, 2020 |
| NCT01839500 | Completed | A Non-Interventional Study of Treatment Pattern and Clinical Outcomes in Chinese Participants With Gastric Cancer | April 25, 2013 | January 9, 2018 | |
| NCT01847001 | Completed | Phase 2 | Study of Propranolol in Newly Diagnosed Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy | October 2012 | October 16, 2019 |
| NCT03783936 | Completed | Phase 2 | Trial of mFOLFOX6 + Trastuzumab + Avelumab in Gastric and Esophageal Adenocarcinomas | January 24, 2019 | August 30, 2022 |
| NCT00003539 | Completed | Phase 2 | Paclitaxel Plus Monoclonal Antibody Therapy in Treating Women With Recurrent or Metastatic Breast Cancer | April 1998 | February 2003 |
| NCT00003612 | Completed | Phase 2 | Combination Chemotherapy and Trastuzumab in Treating Women With Metastatic Breast Cancer | April 1999 | March 15, 2019 |
| NCT00003740 | Completed | Phase 2 | Trastuzumab in Treating Patients With Prostate Cancer | October 1998 | September 2002 |
| NCT00003881 | Completed | Phase 2 | Trastuzumab Plus Chemotherapy in Treating Patients With Advanced Non-small Cell Lung Cancer | May 1999 | July 2004 |
| NCT00003992 | Completed | Phase 2 | Chemotherapy Plus Monoclonal Antibody Therapy in Treating Women With Stage II or Stage IIIA Breast Cancer That Overexpresses HER2 | August 1999 | March 2009 |
| NCT00003995 | Completed | Phase 2 | Monoclonal Antibody Plus Chemotherapy in Treating Patients With Advanced Colorectal Cancer That Overexpresses HER2 | September 1999 | |
| NCT00004013 | Completed | Phase 2 | Paclitaxel With or Without Trastuzumab Following Peripheral Stem Cell Transplantation in Treating Patients With Refractory Stage IV Breast Cancer | January 1999 | October 2001 |
| NCT00004163 | Completed | Phase 2 | Trastuzumab in Treating Patients With Advanced Salivary Gland Cancer | October 1999 | September 2001 |
| NCT00004883 | Completed | Phase 2 | Trastuzumab in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer That Overexpresses HER2 | February 2000 | |
| NCT00004888 | Completed | Phase 2 | Combination Chemotherapy With or Without Trastuzumab in Treating Women With Metastatic Breast Cancer | January 2001 | May 2009 |
| NCT00004925 | Completed | Phase 1/Phase 2 | Liposomal Doxorubicin and Trastuzumab in Treating Women With Locally Advanced, Inflammatory, or Metastatic Breast Cancer | August 1999 | August 2003 |
| NCT00005033 | Completed | Phase 2 | Trastuzumab in Treating Patients With Recurrent Osteosarcoma | December 1999 | August 2004 |
| NCT00005635 | Completed | Phase 2 | Trastuzumab Plus Paclitaxel in Treating Women With Metastatic Breast Cancer That Overexpresses HER2 | January 2000 | |
| NCT00005831 | Completed | Phase 2 | Trastuzumab and Combination Chemotherapy in Treating Patients With Locally Recurrent or Metastatic Urinary Tract Cancer | March 2000 | |
| NCT00005842 | Completed | Phase 1 | Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer | June 2000 | |
| NCT00005857 | Completed | Phase 2 | Trastuzumab and Docetaxel in Treating Patients Who Have Metastatic Prostate Cancer That Is Refractory to Hormone Therapy | August 2000 | October 2002 |
| NCT00005970 | Completed | Phase 3 | Doxorubicin Hydrochloride, Cyclophosphamide, and Pacltaxel With or Without Trastuzumab in Treating Women With HER2-Positive Node-Positive or High-Risk Node-Negative Breast Cancer | May 19, 2000 | January 27, 2010 |
| NCT00006089 | Completed | Phase 2 | Trastuzumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer | September 18, 2000 | January 31, 2010 |
| NCT00006104 | Completed | Phase 2 | Trastuzumab Plus Docetaxel in Treating Women With Recurrent or Metastatic Breast Cancer | September 1998 | July 2003 |
| NCT00006108 | Completed | Phase 1/Phase 2 | Capecitabine, Paclitaxel, and Trastuzumab in Treating Patients With Metastatic Breast Cancer | August 1999 | July 2002 |
| NCT00006110 | Completed | Phase 2 | Multimodality Treatment for Women With Stage II, Stage III, or Stage IV Breast Cancer | December 1998 | April 2013 |
| NCT00006228 | Completed | Phase 2 | Trastuzumab and Interleukin-2 in Treating Patients With Metastatic Breast Cancer | July 2000 | |
| NCT00006381 | Completed | Phase 2 | Celecoxib and Trastuzumab in Treating Women With Metastatic Breast Cancer | June 2000 | February 2004 |
| NCT00006825 | Completed | Phase 1/Phase 2 | Liposomal Doxorubicin and Trastuzumab in Treating Women With Advanced Breast Cancer | July 2000 | |
| NCT00009997 | Completed | Phase 1 | Trastuzumab and Chemotherapy Followed by Surgery and Combination Chemotherapy in Treating Women With Locally Advanced Breast Cancer | March 1999 | |
| NCT00014430 | Completed | Phase 1 | Chemotherapy Plus Trastuzumab in Treating Patients With Breast Cancer | November 1999 | |
| NCT00016367 | Completed | Phase 2 | Cisplatin and Gemcitabine Plus Trastuzumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer | May 13, 1999 | December 14, 2004 |
| NCT00019812 | Completed | Phase 2 | Monoclonal Antibody Plus Chemotherapy in Treating Patients With Metastatic Breast Cancer That Overexpresses HER2 | August 1999 | February 2004 |
| NCT00022529 | Completed | Phase 1 | BMS-214662 Plus Trastuzumab in Treating Patients With Advanced Solid Tumors | July 2001 | |
| NCT00023998 | Completed | Phase 2 | Chemotherapy With or Without Trastuzumab in Treating Patients With Metastatic Osteosarcoma | July 2001 | May 2007 |
| NCT00024154 | Completed | Phase 2 | Trastuzumab and Gefitinib in Treating Patients With Metastatic Breast Cancer | February 2002 | |
| NCT00028535 | Completed | Phase 1 | Interleukin-12, Paclitaxel, and Trastuzumab in Treating Patients With Solid Tumors | November 2001 | |
| NCT00033514 | Completed | Phase 1/Phase 2 | Trastuzumab and Erlotinib as First-Line Therapy in Treating Women With Metastatic Breast Cancer Associated With HER2/Neu Overexpression | August 2001 | December 2011 |
| NCT00036868 | Completed | Phase 2 | Combination Chemotherapy With Trastuzumab in Treating Women With Metastatic Breast Cancer | February 2002 | February 2010 |
| NCT00041067 | Completed | Phase 2 | S0215 Trastuzumab, Docetaxel, Vinorelbine, and Filgrastim in Treating Women With Stage IV Breast Cancer | September 2002 | January 2012 |
| NCT00042809 | Completed | Phase 1 | Erlotinib, Trastuzumab, and Paclitaxel in Treating Patients With Advanced Solid Tumors | May 2002 | |
| NCT00047255 | Completed | Phase 3 | Docetaxel and Trastuzumab With or Without Carboplatin in Treating Women With HER2-Positive Breast Cancer | May 2002 | April 2010 |
| NCT00054587 | Completed | Phase 3 | Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer | June 2001 | December 2009 |
| NCT00068341 | Completed | Phase 2 | Docetaxel and Carboplatin With or Without Trastuzumab Before Surgery in Treating Women With Locally Advanced Breast Cancer | July 2003 | November 2013 |
| NCT00068757 | Completed | Phase 1 | Lonafarnib, Trastuzumab, and Paclitaxel in Treating Patients With HER2/Neu-Overexpressing Stage IIIB, Stage IIIC, or Stage IV Breast Cancer | August 2003 | |
| NCT00077376 | Completed | Phase 2 | Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast Cancer | March 2005 | March 2011 |
| NCT00084513 | Completed | Phase 1 | Trastuzumab and Imatinib Mesylate in Treating Patients With Recurrent or Metastatic HER2/Neu-Expressing Cancer | August 2004 | March 2007 |
| NCT00085020 | Completed | Phase 1 | GW572016 and Trastuzumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER2/Neu | March 2004 | February 2005 |
| NCT00086957 | Completed | Phase 1/Phase 2 | Gefitinib, Trastuzumab, and Docetaxel in Treating Patients With Metastatic Breast Cancer | January 2004 | August 2015 |
| NCT00093808 | Completed | Phase 2 | Capecitabine, Vinorelbine, and Trastuzumab in Treating Patients With Metastatic Breast Cancer | August 2004 | May 2013 |
| NCT00103233 | Completed | Phase 3 | Vinorelbine With or Without Trastuzumab in Treating Women With Progressive Metastatic Breast Cancer | December 2004 | April 2006 |
| NCT00104949 | Completed | Phase 2 | Trastuzumab in Treating Patients With Locally Advanced or Metastatic Synovial Sarcoma | July 2005 | August 2007 |
| NCT00107393 | Completed | Phase 2 | Trastuzumab and Capecitabine in Treating Women With Metastatic Breast Cancer | June 2003 | November 2008 |
| NCT00134680 | Completed | Phase 2 | Letrozole, Herceptin in Her2neu +, Estrogen Receptor [ER] and/or Progesterone Receptor [PR] Positive, MBC | January 2000 | July 2005 |
| NCT00146042 | Completed | Phase 2 | UMCC 9901: Phase II Study of Tailored-Dose Docetaxel + Trastuzumab in Her-2 Positive Metastatic Breast Cancer | March 1999 | March 2005 |
| NCT00146549 | Completed | Phase 3 | Trastuzumab in Combination With Vinorelbine or Taxane-Based Chemotherapy in Patients With Metastatic Breast Cancer | August 2001 | December 2007 |
| NCT00148876 | Completed | Phase 3 | TBP Study With Capecitabine Plus Minus Trastuzumab | September 2003 | January 2011 |
| NCT00151034 | Completed | Phase 2 | Trastuzumab (Herceptin), Paclitaxel, Carboplatin and Gemcitabine in Advanced Urothelial Cancer | September 2000 | October 2007 |
| NCT00182793 | Completed | Phase 2 | Combination Chemotherapy With or Without Trastuzumab Followed By an Autologous Stem Cell Transplant and Radiation Therapy in Treating Patients With Stage III or Stage IV Breast Cancer | July 2005 | October 2014 |
| NCT00191373 | Completed | Phase 2 | A Trial for HER2 Positive Breast Cancer Patients With Metastatic Disease | March 2002 | July 2007 |
| NCT00193063 | Completed | Phase 2 | Weekly Gemcitabine and Trastuzumab in the Treatment of Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Metastatic Breast Cancer | July 2001 | August 2009 |
| NCT00193076 | Completed | Phase 2 | Combination Gemcitabine, Carboplatin With or Without Trastuzumab in Patients With Metastatic Breast Cancer | November 2003 | October 2008 |
| NCT00193089 | Completed | Phase 2 | Docetaxel, Vinorelbine and Trastuzumab in the Treatment of Patients With Metastatic Her-2 Positive Breast Cancer | April 2001 | September 2009 |
| NCT00194779 | Completed | Phase 2 | Combination Chemotherapy and Filgrastim Before Surgery in Treating Patients With HER2-Positive Breast Cancer That Can Be Removed By Surgery | October 2003 | June 2011 |
| NCT00201760 | Completed | Phase 2 | Gemcitabine/ Trastuzumab and Gemcitabine/ Cisplatin/ Trastuzumab in Patients With Metastatic Breast Cancer | February 25, 2005 | October 31, 2009 |
| NCT00238420 | Completed | Phase 1/Phase 2 | Paclitaxel and Radiation Therapy With or Without Trastuzumab in Treating Patients Who Have Undergone Surgery for Bladder Cancer | July 26, 2005 | May 20, 2022 |
| NCT00242203 | Completed | Phase 2 | Evaluation of Chemotherapy Prior to Surgery With or Without Zometa for Women With Locally Advanced Breast Cancer | October 2002 | May 2011 |
| NCT00254592 | Completed | Phase 2 | Neoadjuvant Treatment of Breast Cancer | October 2005 | September 4, 2013 |
| NCT00256243 | Completed | Phase 2 | Neoadjuvant Biweekly Treatment Followed by Weekly Treatment of Breast Cancer | April 2004 | July 2012 |
| NCT00258349 | Completed | Phase 1/Phase 2 | Vorinostat and Trastuzumab in Treating Patients With Metastatic or Locally Recurrent Breast Cancer | August 2006 | September 2010 |
| NCT00258960 | Completed | Phase 2 | Caelyx, Cyclophosphamide and Herceptin in Patients With Metastatic Breast Cancer | February 15, 2006 | July 14, 2009 |
| NCT00266110 | Completed | Phase 2 | Vaccine Therapy, Trastuzumab, and Vinorelbine in Treating Patients With Locally Recurrent or Metastatic Breast Cancer | December 2005 | October 27, 2017 |
| NCT00270894 | Completed | Phase 2 | Neoadjuvant Chemotherapy + Herceptin in HER2 Positive Stage II-III Breast Cancer Patients | November 2005 | August 2011 |
| NCT00284180 | Completed | Phase 2 | Vinflunine Plus Trastuzumab in Human Epidermal Growth Factor Receptor 2 (HER2neu) Over-Expressing Metastatic Breast Cancer | January 2006 | November 2010 |
| NCT00288002 | Completed | Phase 3 | Combination Chemotherapy With or Without Capecitabine and/or Trastuzumab Before Surgery in Treating Women With Stage I, Stage II, or Stage III Breast Cancer | January 2005 | |
| NCT00297596 | Completed | Phase 2 | Trastuzumab and Oxaliplatin in Patients With Metastatic Breast Cancer | February 2006 | October 2010 |
| NCT00301730 | Completed | Phase 1 | Cellular Adoptive Immunotherapy in Treating a Patient Who Has Undergone a Donor Stem Cell Transplant for Breast Cancer That Has Spread to the Lung | October 2005 | |
| NCT00301899 | Completed | Phase 2 | Trastuzumab and Pertuzumab in Treating Patients With Unresectable Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Previous Trastuzumab | December 2005 | October 2007 |
| NCT00303108 | Completed | Phase 2 | Doxil & Carboplatin Plus HER2+ in Metastatic Breast Cancer | December 2005 | June 2011 |
| NCT00303992 | Completed | Phase 2 | Trastuzumab and Irinotecan in Treating Patients With HER2/Neu Positive Metastatic Breast Cancer | May 2004 | January 2013 |
| NCT00309556 | Completed | Phase 3 | Randomized Neoadjuvant Study of Epirubicin and Docetaxel With/Without Capecitabine in Early Breast Cancer | February 2005 | November 2011 |
| NCT00317720 | Completed | Phase 1/Phase 2 | Trastuzumab and RAD001 in Patients With Human Epidermal Growth Receptor 2 (HER-2) Overexpressing Breast Cancer | April 2006 | February 2013 |
| NCT00320385 | Completed | Phase 3 | Lapatinib In Combination With Trastuzumab Versus Lapatinib Monotherapy In Subjects With HER2-positive Metastatic Breast Cancer | November 2005 | October 2010 |
| NCT00331552 | Completed | Phase 1/Phase 2 | Doxorubicin Hydrochloride Liposome, Cyclophosphamide, and Trastuzumab in Treating Patients With Stage IV Breast Cancer | February 2006 | February 2012 |
| NCT01855828 | Completed | Phase 2 | Phase 2 Trial of Pertuzumab and Trastuzumab With Weekly Paclitaxel and Chemotherapy for HER2 Positive Breast Cancer | September 2013 | August 2018 |
| NCT01875666 | Completed | Early Phase 1 | Defining the HER2 Positive (+) Breast Cancer Kinome Response to Trastuzumab, Pertuzumab, Combination Trastuzumab +Pertuzumab, or Combination Trastuzumab + Lapatinib | August 5, 2013 | December 19, 2016 |
| NCT01894711 | Completed | Real World Efficiency of Trastuzumab in Early Breast Cancer | May 2010 | May 2013 | |
| NCT01901146 | Completed | Phase 3 | Efficacy and Safety Study of ABP 980 Compared With Trastuzumab in Women With HER2-positive Early Breast Cancer | April 29, 2013 | January 27, 2017 |
| NCT01904903 | Completed | Phase 2 | Cardiac Safety Study in Patients With HER2 + Breast Cancer | October 2013 | June 2020 |
| NCT01921335 | Completed | Phase 1 | ARRY-380 + Trastuzuamab for Breast w/ Brain Mets | August 2013 | December 31, 2023 |
| NCT01922921 | Completed | Phase 1/Phase 2 | Vaccine Therapy With or Without Polysaccharide-K in Patients With Stage IV HER2 Positive Breast Cancer Receiving HER2-Targeted Monoclonal Antibody Therapy | February 5, 2014 | September 1, 2021 |
| NCT01926886 | Completed | Phase 3 | A Study of Subcutaneous At Home Administration of Trastuzumab (Herceptin) in Participants With Human Epidermal Growth Factor Receptor 2-positive (HER2+) Early Breast Cancer (eBC) | November 19, 2013 | July 19, 2017 |
| NCT01928290 | Completed | Phase 2 | Combination Chemotherapy in Treating Patients With Advanced Stomach, Gastroesophageal, or Esophageal Cancer | November 8, 2013 | October 28, 2019 |
| NCT01940497 | Completed | Phase 3 | A Study of the Safety of Subcutaneously Administered Trastuzumab (Herceptin) in Participants With Early and Locally Advanced Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer | November 15, 2013 | March 27, 2018 |
| NCT01959386 | Completed | A Study of Trastuzumab Subcutaneous in Participants With Human Epidermal Growth Factor Receptor-2 (HER2) Positive Early Breast Cancer | November 7, 2013 | January 31, 2019 | |
| NCT01959490 | Completed | Phase 2 | Trastuzumab and Pertuzumab or Bevacizumab With Combination Chemotherapy in Treating Patients With Stage II-III Breast Cancer | September 24, 2013 | March 29, 2017 |
| NCT01964391 | Completed | Phase 3 | A Study of Participant Satisfaction and Safety With Subcutaneously Administered Trastuzumab (Herceptin) in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer | February 21, 2014 | November 25, 2018 |
| NCT01966471 | Completed | Phase 3 | A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer | January 31, 2014 | June 4, 2021 |
| NCT01969643 | Completed | Phase 1 | A Safety Study of SGN-LIV1A in Breast Cancer Patients | October 22, 2013 | February 4, 2023 |
| NCT01973660 | Completed | Phase 2 | PAM50 HER2-enriched Phenotype as a Predictor of Response to Dual HER2 Blockade in HER2-positive Early Breast Cancer | October 2013 | December 2017 |
| NCT01998906 | Completed | Phase 3 | A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Women With Locally Advanced Breast Cancer | May 2002 | July 2012 |
| NCT02000882 | Completed | Phase 2 | STAR Cape+BKM120 MBC With Brain Met | May 29, 2014 | March 29, 2019 |
| NCT02004769 | Completed | Phase 2 | Trastuzumab Plus Docetaxel and Capecitabine For First Line Treatment of Her2-Positive Advanced Gastric Cancer | November 2013 | June 2016 |
| NCT02006667 | Completed | Phase 2 | A Study of Herceptin (Trastuzumab) Combination Therapy in Patients With Metastatic Urothelial Cancer | January 2001 | January 2010 |
| NCT02015676 | Completed | Phase 1/Phase 2 | A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Patients With Metastatic or Locally Advanced Breast Cancer | July 2001 | September 2009 |
| NCT02019277 | Completed | Phase 3 | A Study of Pertuzumab and Trastuzumab Subcutaneous (SC) Treatment in Combination With a Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer | December 5, 2013 | November 4, 2016 |
| NCT02025192 | Completed | Phase 1 | A Study of Tucatinib (ONT-380) Combined With Capecitabine and/or Trastuzumab in Patients With HER2+ Metastatic Breast Cancer | December 31, 2013 | March 16, 2020 |
| NCT02040935 | Completed | Phase 3 | A Study of SC Administration of Trastuzumab (Herceptin) by SID at Home in HER2-Positive EBC Participants | February 21, 2014 | September 14, 2018 |
| NCT02060253 | Completed | Phase 1 | Ganetespib, Paclitaxel, Trastuzumab and Pertuzumab for Metastatic Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer | April 2014 | June 2018 |
| NCT02066532 | Completed | Phase 1/Phase 2 | Ruxolitinib in Combination With Trastuzumab in Metastatic HER2 Positive Breast Cancer | June 2014 | October 14, 2020 |
| NCT02073487 | Completed | Phase 2 | Neoadjuvant TDM1 With Lapatinib and Abraxane Compared With Trastuzumab Plus Pertuzumab With Paclitaxel | February 2014 | January 2019 |
| NCT02091141 | Completed | Phase 2 | My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors | April 14, 2014 | May 24, 2023 |
| NCT02091960 | Completed | Phase 2 | A Study to Assess the Efficacy and Safety of Enzalutamide With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2 Positive (HER2+), Androgen Receptor Positive (AR+) Metastatic or Locally Advanced Breast Cancer | September 5, 2014 | January 30, 2024 |
| NCT02100917 | Completed | Phase 1 | Bioequivalence Study Evaluating the Pharmacokinetics of DMB-3111 and Trastuzumab in Healthy Japanese Male Adults | January 2014 | December 2014 |
| NCT02125344 | Completed | Phase 3 | A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto) | December 2014 | January 30, 2017 |
| NCT02131064 | Completed | Phase 3 | A Study Evaluating Trastuzumab Emtansine Plus Pertuzumab Compared With Chemotherapy Plus Trastuzumab and Pertuzumab for Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer | June 25, 2014 | May 29, 2018 |
| NCT02132949 | Completed | Phase 2 | A Study Evaluating Pertuzumab (Perjeta) Combined With Trastuzumab (Herceptin) and Standard Anthracycline-based Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced, Inflammatory, or Early-stage Breast Cancer | July 14, 2014 | August 25, 2020 |
| NCT02139358 | Completed | Phase 1/Phase 2 | Phase I/IIa Trial of Gemcitabine Plus Trastuzumab and Pertuzumab in Previously Treated Metastatic HER2+ Breast Cancer | September 5, 2014 | March 16, 2020 |
| NCT02152943 | Completed | Phase 1 | Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive Patients | July 17, 2014 | December 14, 2020 |
| NCT02162667 | Completed | Phase 3 | Efficacy and Safety Evaluating Study of CT-P6 in Her2 Positive Early Breast Cancer | June 2014 | October 2018 |
| NCT02167854 | Completed | Phase 1 | Open-Label Study Evaluating the Safety and Tolerability of LJM716, BYL719 and Trastuzumab in Patients With Metastatic HER2+ Breast Cancer | June 16, 2014 | July 7, 2021 |
| NCT02194166 | Completed | Phase 3 | A Study to Investigate the Tolerability of Subcutaneous (SC) Trastuzumab Administration in Participants With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Early Breast Cancer (eBC) Using Either a Single-Use Injection Device or Manual Administration | July 18, 2014 | July 12, 2018 |
| NCT02213289 | Completed | Phase 2 | PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A 1st Pilot Metastatic Trial of Biologics Beyond Progression | January 20, 2015 | August 20, 2020 |
| NCT02260531 | Completed | Phase 2 | Cabozantinib +/- Trastuzumab In Breast Cancer Patients w/ Brain Metastases | November 2014 | March 17, 2020 |
| NCT02291289 | Completed | Phase 2 | A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC) | April 17, 2015 | March 24, 2021 |
| NCT02297698 | Completed | Phase 2 | Phase II Trial of Combination Immunotherapy With NeuVax and Trastuzumab in High-risk HER2+ Breast Cancer Patients | October 2014 | December 2021 |
| NCT02307227 | Completed | Phase 2 | Phase II Study With Trastuzumab + Paclitaxel in Locally Advanced HER2+ Tumors or Epirubicin + Taxotere in HER2- Tumors | April 2006 | April 2014 |
| NCT02419742 | Completed | Phase 4 | Safety and Efficacy of Trastuzumab as Part of Breast Cancer Treatment Regimen | August 18, 2015 | June 24, 2021 |
| NCT02445586 | Completed | Phase 4 | Safety Study of Pertuzumab (in Combination With Trastuzumab and Docetaxel) in Indian Participants With Breast Cancer | August 17, 2015 | September 26, 2018 |
| NCT02448420 | Completed | Phase 2 | Study of Palbociclib and Trastuzumab With Endocrine Therapy in HER2-positive Metastatic Breast Cancer | July 2015 | November 30, 2023 |
| NCT02472964 | Completed | Phase 3 | Study of Efficacy and Safety of Myl1401O + Taxane vs Herceptin©+ Taxane for 1st Line, Met. Br. Ca. | July 2012 | August 2018 |
| NCT02488564 | Completed | Phase 2 | A Study of Liposomal Doxorubicin + Docetaxel + Trastuzumab + Metformin in Operable and Locally Advanced HER2 Positive Breast Cancer | December 17, 2014 | April 2020 |
| NCT02492711 | Completed | Phase 3 | Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer | August 24, 2015 | June 14, 2022 |
| NCT02530424 | Completed | Phase 2 | "Neo-Adjuvant Treatment With Palbociclib: Effect on Ki67 and Apoptosis Before, During and After Treatment " | May 2015 | November 2019 |
| NCT02536339 | Completed | Phase 2 | A Study of Pertuzumab With High-Dose Trastuzumab for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (MBC) With Central Nervous System (CNS) Progression Post-Radiotherapy | December 16, 2015 | December 29, 2020 |
| NCT02586025 | Completed | Phase 3 | Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel | March 14, 2016 | March 14, 2022 |
| NCT02605915 | Completed | Phase 1 | Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast Cancer | December 31, 2015 | November 13, 2019 |
| NCT02614794 | Completed | Phase 2 | A Study of Tucatinib vs. Placebo in Combination With Capecitabine & Trastuzumab in Patients With Advanced HER2+ Breast Cancer | January 28, 2016 | August 11, 2022 |
| NCT02627274 | Completed | Phase 1 | A Study Evaluating Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281 as a Single Agent (Part A) or in Combination With Trastuzumab or Cetuximab (Part B or C) | December 7, 2015 | November 10, 2022 |
| NCT02649686 | Completed | Phase 1 | Durvalumab in Patients With HER-2 Positive Metastatic Breast Cancer Receiving Trastuzumab | May 17, 2016 | November 12, 2019 |
| NCT02657343 | Completed | Phase 1/Phase 2 | An Open-Label, Phase Ib/II Clinical Trial Of Cdk 4/6 Inhibitor, Ribociclib (Lee011), In Combination With Trastuzumab Or T-Dm1 For Advanced/Metastatic Her2-Positive Breast Cancer. | March 9, 2016 | June 30, 2022 |
| NCT02658461 | Completed | An Observational Time and Motion Study of Trastuzumab Subcutaneous (SC) and Intravenous (IV) Formulations in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (EBC) | February 2012 | February 2013 | |
| NCT02665637 | Completed | Phase 1 | Study Comparing Pharmacokinetics, Safety and Immunogenicity of CT-P6 and US-licensed Herceptin | December 2015 | April 2016 |
| NCT02675231 | Completed | Phase 2 | A Study of Abemaciclib (LY2835219) in Women With HR+, HER2+ Locally Advanced or Metastatic Breast Cancer | May 23, 2016 | November 9, 2023 |
| NCT02682693 | Completed | Phase 2 | Denosumab as an add-on Neoadjuvant Treatment (GeparX) | February 13, 2017 | December 31, 2020 |
| NCT02705859 | Completed | Phase 1 | Phase Ib/II Trial of coPANlisib in Combination With Trastuzumab in HER2-positive Breast Cancer. (Panther Study) | April 2016 | July 2022 |
| NCT02725424 | Completed | Phase 2 | Optimizing the Strategy for Preoperative Chemotherapy in Locally Advanced Gastric/Gastroesophageal Cancer | August 2015 | June 2019 |
| NCT02731313 | Completed | Human Epidermal Growth Factor Receptor 2 (HER-2) Status in Gastric and Gastro-Esophageal Junction (GEJ) Carcinoma | July 2012 | October 2014 | |
| NCT02738970 | Completed | Phase 1 | A Dose-Finding Study of Pertuzumab (Perjeta) in Combination With Trastuzumab (Herceptin) in Healthy Male Participants and Women With Early Breast Cancer (EBC) | June 23, 2016 | May 31, 2018 |
| NCT02789657 | Completed | Phase 2 | Neoadjuvant Therapy in Clinical Stage I-III HER2-positive Breast Cancer. | November 21, 2016 | March 27, 2020 |
| NCT02843126 | Completed | Phase 1/Phase 2 | Combination of Trastuzumab and NK Immunotherapy for Recurrent Breast Cancer | July 1, 2016 | July 1, 2019 |
| NCT02896855 | Completed | Phase 3 | A Study to Evaluate the Efficacy and Safety of Pertuzumab + Trastuzumab + Docetaxel Versus Placebo + Trastuzumab + Docetaxel in Previously Untreated Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer | September 13, 2016 | January 22, 2021 |
| NCT02954536 | Completed | Phase 2 | Phase II Trial of Pembrolizumab With Trastuzumab and Chemotherapy in Advanced HER2 Positive Esophagogastric (EG) Cancer | November 3, 2016 | March 14, 2023 |
| NCT03014076 | Completed | Phase 1 | Immunotherapy Vaccine and Herceptin in Breast Cancer | January 2008 | January 2017 |
| NCT03043313 | Completed | Phase 2 | Tucatinib Plus Trastuzumab in Patients With HER2+ Colorectal Cancer | June 23, 2017 | November 2, 2023 |
| NCT03094052 | Completed | Phase 2 | Incidence and Severity of Diarrhea in Patients With HER2 Positive Breast Cancer Treated With Trastuzumab and Neratinib | October 9, 2018 | October 31, 2022 |
| NCT03112590 | Completed | Phase 1/Phase 2 | Phase I-II Study of Interferon-gamma in Patients With HER-2 Positive Breast Cancer | June 23, 2017 | February 20, 2023 |
| NCT03135171 | Completed | Phase 1 | Trastuzumab and Pertuzumab in Combination With Tocilizumab in Subjects With Metastatic HER2 Positive Breast Cancer Resistant to Trastuzumab | July 26, 2017 | March 20, 2020 |
| NCT03319459 | Completed | Phase 1 | FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors | January 18, 2018 | December 15, 2020 |
| NCT03321981 | Completed | Phase 2 | MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer. | January 15, 2018 | July 26, 2023 |
| NCT03364348 | Completed | Phase 1 | 4-1BB Agonist Monoclonal Antibody PF-05082566 With Trastuzumab Emtansine or Trastuzumab in Treating Patients With Advanced HER2-Positive Breast Cancer | October 30, 2017 | February 14, 2022 |
| NCT03613168 | Completed | Phase 2 | Trastuzumab in HER2-positive Biliary Tract Cancer | June 1, 2019 | January 4, 2021 |
| NCT03644186 | Completed | Phase 2 | To Reduce the Use of Chemotherapy in Postmenopausal Patients With ER-positive and HER2-positive Breast Cancer (TOUCH) | April 16, 2019 | April 14, 2023 |
| NCT03726879 | Completed | Phase 3 | A Study To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast Cancer | January 11, 2019 | August 24, 2023 |
| NCT03767335 | Completed | Phase 1 | MEN1611 With Trastuzumab (+/- Fulvestrant) in Metastatic Breast Cancer | July 19, 2018 | February 23, 2024 |
| NCT00003440 | Completed | Phase 3 | Paclitaxel With or Without Trastuzumab in Treating Patients With or Without HER-2/Neu Breast Cancer That is Inoperable, Recurrent, or Metastatic | July 1998 | |
| NCT04049409 | Completed | Phase 1 | Pharmacokinetic, Safety and Immunogenicity Study of CMAB809 and Herceptin in Healthy Volunteers | June 17, 2019 | November 20, 2019 |
| NCT04629846 | Completed | Phase 3 | Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive and Estrogen Receptor/Progesterone Receptor Negative Breast Cancer to Evaluate the Efficiency and Safety of Treatment With Trastuzumab Plus (+) QL1209/Pertuzumab + Docetaxel. | November 23, 2020 | October 24, 2023 |
| NCT04957212 | Completed | Phase 3 | Comparing Efficacy and Safety Between Pertuzumab® and Perjeta® in Neoadjuvant Treatment of HER2+ Breast Cancer | August 11, 2018 | May 27, 2020 |
| NCT05931042 | Completed | Neoadjuvant Therapy With Trastuzumab and Chemotherapy and the Resultant Pathologic Complete Response Observed in HER2 Positive Breast Cancer;a Systematic Review | June 1, 2023 | June 18, 2023 | |
| NCT05997524 | Completed | Phase 2 | Clinical Efficacy of Trastuzumab in Combination With Capecitabine and Oxaliplatin for the Treatment of HER2-positive Advanced Gastric Cancer. | March 1, 2021 | June 30, 2023 |
| NCT06021379 | Completed | AryoTrust® (Trastuzumab) Safety Study | February 22, 2017 | August 28, 2022 | |
| NCT06107790 | Completed | Phase 3 | Phase III Clinical Trial Comparing the Safety, Efficacy, and Immunogenicity of HS022 and Trastuzumab® in Combination With Vinorelbine Bitartrate Injection in the Treatment of HER2-positive Breast Cancer | May 16, 2018 | January 28, 2022 |
| NCT05193292 | Not yet recruiting | Phase 2 | Camrelizumab Combined With Trastuzumab and Chemotherapy in Patients With HER2-positive Advanced Colorectal Cancer | January 2022 | January 2025 |
| NCT05983094 | Not yet recruiting | Phase 2 | Study of Utidelone Based Neoadjuvant Treatment on Early High-risk or Locally Advanced Breast Cancer | September 1, 2023 | September 1, 2027 |
| NCT05838066 | Not yet recruiting | Phase 3 | Efficacy and Safety of KN026 in Combination With HB1801 in the First-line Treatment of Subjects With HER2-positive Recurrent or Metastatic Breast Cancer. | July 2023 | December 2027 |
| NCT04158856 | Not yet recruiting | Phase 2 | Adjuvant Dual Anti-HER2 Therapy in Patients With Small, Node-negative, HER2-positive Breast Cancer | June 1, 2020 | May 31, 2030 |
| NCT05356897 | Not yet recruiting | Phase 2 | Tucatinib Combined With Trastuzumab and TAS-102 for the Treatment of HER2 Positive Metastatic Colorectal Cancer in Molecularly Selected Patients, 3T Study | November 30, 2023 | May 30, 2029 |
| NCT06439693 | Not yet recruiting | Phase 2 | The SAPPHO Study: A Single-Arm, Phase II Study of Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer | November 2024 | March 30, 2033 |
| NCT05577923 | Not yet recruiting | Phase 2 | Exploring Whether Disease-free Intervals Can Guide Endocrine Combined Targeted Therapy for ER+/HER2+ Advanced Breast Cancer (T-sunflower) | November 1, 2022 | March 1, 2026 |
| NCT05388500 | Not yet recruiting | Phase 3 | Protocol for Herceptin as Adjuvant Therapy With Reduced Exposure to Chemotherapy (PHARE-C) | December 15, 2022 | December 15, 2030 |
| NCT04337658 | Not yet recruiting | Phase 3 | Anti-HER2 Therapy + Fulvestrant/Capecitabine in Women With HR+, HER2+, Non-visceral Metastases Stage IV Breast Cancer | July 1, 2020 | April 30, 2026 |
| NCT06439550 | Not yet recruiting | Phase 2 | Adjuvant Treatment With Serplulimab，Trastuzumab and SOX in the HER-2 Positive GC/GEJC | July 15, 2024 | December 31, 2026 |
| NCT05131893 | Not yet recruiting | Neoadjuvant Treatment of Breast Cancer | March 2022 | December 2031 | |
| NCT05841381 | Not yet recruiting | Phase 3 | Adjuvant Study of Pyrotinib in Combination With Trastuzumab in HER2 Positive Invasive Breast Cancer | May 6, 2023 | May 6, 2033 |
| NCT06435429 | Not yet recruiting | Phase 3 | A Phase 3, Randomized, Open-label, Controlled Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer | July 16, 2024 | April 25, 2031 |
| NCT04973319 | Not yet recruiting | Phase 3 | Trastuzumab Combined With Pertuzumab for Adjuvant Treatment of Breast Cancer After Neoadjuvant Therapy | August 1, 2021 | August 1, 2027 |
| NCT06245356 | Not yet recruiting | Phase 2 | Safety of Trifluridine/Tipiracil in Patients With Dihydropyrimidine Dehydrogenase Deficiency Diagnosed With Metastatic Colorectal or Gastroesophageal Cancer | June 20, 2024 | June 21, 2028 |
| NCT05901935 | Not yet recruiting | Phase 3 | DP303c in Patients With HER2-positive Advanced Breast Cancer | July 2023 | July 2028 |
| NCT04760431 | Not yet recruiting | Phase 2 | TKIs vs. Pertuzumab in HER2+ Breast Cancer Patients With Active Brain Metastases (HER2BRAIN) | October 1, 2021 | September 30, 2025 |
| NCT05218148 | Not yet recruiting | Phase 2 | SOX Combined With Sintilimab and Trastuzumab Versus SOX Regimen in the Perioperative Treatment of HER2-positive Locally Advanced Gastric Adenocarcinoma | April 1, 2022 | December 1, 2025 |
| NCT04789096 | Recruiting | Phase 2 | Tucatinib Together With Pembrolizumab and Trastuzumab | March 7, 2023 | September 2025 |
| NCT04329065 | Recruiting | Phase 2 | Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast Cancer | April 20, 2022 | June 30, 2027 |
| NCT04379596 | Recruiting | Phase 2 | Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03) | June 3, 2020 | July 30, 2026 |
| NCT05420454 | Recruiting | Phase 4 | A Study for the Neoadjuvant Treatment of Breast Cancer | July 10, 2022 | December 20, 2027 |
| NCT05656079 | Recruiting | N/A | To Evaluate the Cardiac Safety of Pegylated Liposomal Doxorubicin Concurrently Plus Trastuzumab and Pertuzumab in the Adjuvant Setting for Early-stage HER-2-positive Breast Cancer: a Multicenter, Randomized Controlled Clinical Study | July 1, 2021 | September 2025 |
| NCT04430738 | Recruiting | Phase 1/Phase 2 | Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers | September 15, 2020 | October 31, 2025 |
| NCT04680442 | Recruiting | Phase 2 | Safety of Continuing HER-2 Directed Therapy in Overt Left Ventricular Dysfunction | July 1, 2021 | June 1, 2025 |
| NCT05583110 | Recruiting | Phase 2 | Efficacy and Safety of the Combination of Trastuzumab Plus TUCAtinib Plus viNorelbine in Patients With HER2-positive Non-resectable Locally Advanced or Metastatic Breast Cancer | March 8, 2023 | August 2026 |
| NCT06278870 | Recruiting | Phase 3 | Disitamab Vedotin + Pyrotinib Versus THP in the First-line Treatment for HER2+ Advanced Breast Cancer Clinical Trial | September 6, 2023 | June 30, 2031 |
| NCT04551521 | Recruiting | Phase 2 | CRAFT: The NCT-PMO-1602 Phase II Trial | October 13, 2021 | June 30, 2025 |
| NCT05672524 | Recruiting | Phase 2 | A Study of Tucatinib and Trastuzumab in People With Rectal Cancer | December 30, 2022 | December 30, 2025 |
| NCT04588545 | Recruiting | Phase 1/Phase 2 | Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal Disease | December 10, 2020 | November 1, 2024 |
| NCT05408845 | Recruiting | Phase 2 | Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) for Recurrent, Metastatic, or Unresectable HER2-Positive Salivary Gland Cancer | September 30, 2022 | July 31, 2028 |
| NCT06016387 | Recruiting | Phase 2 | Tucatinib With Brain and/or Spinal XRT in Patients With HER2+ Metastatic Breast Cancer and LMD | November 25, 2023 | October 5, 2028 |
| NCT06031233 | Recruiting | Phase 4 | Evaluating the Safety of Shortened Infusion Times for dIfferent Oncological Immunotherapie | September 1, 2023 | December 2024 |
| NCT05615818 | Recruiting | Phase 3 | Personalized Medicine for Advanced Biliary Cancer Patients | May 29, 2024 | June 2028 |
| NCT05582499 | Recruiting | Phase 1/Phase 2 | Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy | November 1, 2022 | September 2025 |
| NCT06100874 | Recruiting | Phase 2 | A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After Trastuzumab dEruxtEcaN (SATEEN) | November 20, 2023 | November 30, 2027 |
| NCT05715931 | Recruiting | Phase 2 | Perioperative Chemotherapy Plus Trastuzumab Plus Toripalimab in HER2 Positive Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma | February 28, 2023 | March 1, 2028 |
| NCT06441890 | Recruiting | Phase 2 | BRE-10: Biomarker Optimization of Neoadjuvant Therapy in Breast Cancer | June 2024 | June 2028 |
| NCT05720026 | Recruiting | Phase 3 | Study to Evaluate the Efficacy and Safety of SYSA1901 vs. Perjeta® of HER2-Positive Breast Cancer | January 9, 2023 | February 21, 2026 |
| NCT03199300 | Recruiting | Investigating Cardiovascular Adverse Events Related to Cancer Treatment | December 12, 2017 | January 2025 | |
| NCT05725200 | Recruiting | Phase 2 | Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer | September 27, 2022 | December 31, 2040 |
| NCT05385705 | Recruiting | Phase 1 | A Study of Allogenic Natural Killer Cells in Combination With Trastuzumab and Pertuzumab in Adult Patients With Refractory Metastatic Her2 Positive Breast Cancer. NK-ACT-BC_2020 | May 11, 2022 | April 11, 2027 |
| NCT05378464 | Recruiting | Phase 1 | Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine & Pepinemab /Trastuzumab in Patients w/ Metastatic HER2+ Breast Cancer | May 31, 2022 | July 2026 |
| NCT05786716 | Recruiting | Phase 2/Phase 3 | DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Teenage/Young Adult and Paediatric Patients With Cancers With HER2 Amplification or Activating Mutations | March 7, 2023 | October 2029 |
| NCT06109467 | Recruiting | Phase 2 | Neratinib In Combination With Chemotherapy/Trastuzumab/Pembrolizumab In HER2 Gastroesophageal Cancer | January 12, 2024 | April 2028 |
| NCT06121700 | Recruiting | Phase 2 | Radiotherapy + Chemoimmunotherapy Followed by Surgery in Patients With Limited Metastatic Gastric or GEJ Cancer | January 1, 2023 | December 31, 2027 |
| NCT02678182 | Recruiting | Phase 2 | Planning Treatment for Oesophago-gastric Cancer: a Maintenance Therapy Trial | February 2015 | June 2027 |
| NCT06123338 | Recruiting | Phase 2 | A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer | February 1, 2024 | November 30, 2027 |
| NCT05376878 | Recruiting | Phase 4 | An Investigational Scan (64Cu-DOTA-Trastuzumab PET/MRI) in Imaging Patients With HER2+ Breast Cancer With Brain Metastasis | December 21, 2022 | February 25, 2026 |
| NCT03368729 | Recruiting | Phase 1/Phase 2 | Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer | September 6, 2019 | December 30, 2024 |
| NCT03412643 | Recruiting | Phase 2 | Study of Neoadjuvant Chemotherapy Plus Trastuzumab and Pertuzumab in HER2-Negative Breast Cancer Patients With Abnormal HER2 Signaling | May 14, 2018 | October 30, 2023 |
| NCT00781612 | Recruiting | Phase 2 | A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies | October 16, 2008 | September 20, 2029 |
| NCT05325632 | Recruiting | Phase 2 | Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab | October 28, 2021 | January 31, 2025 |
| NCT05323955 | Recruiting | Phase 2 | Secondary BRain Metastases Prevention After Isolated Intracranial Progression on Trastuzumab/Pertuzumab or T-DM1 in Patients With aDvanced Human Epidermal Growth Factor Receptor 2+ brEast Cancer With the Addition of Tucatinib | March 23, 2023 | October 2027 |
| NCT05319873 | Recruiting | Phase 1/Phase 2 | Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer | April 7, 2022 | April 1, 2026 |
| NCT05318339 | Recruiting | Phase 2 | A Study of Trastuzumab and Pyrotinib in HER2 Positive Locally Advanced or Metastatic Urothelial Carcinoma | March 10, 2022 | December 10, 2024 |
| NCT05253651 | Recruiting | Phase 3 | A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer | October 24, 2022 | April 30, 2028 |
| NCT05883852 | Recruiting | Phase 3 | EC-THP Versus TCbHP in HER2-positive Lymph Node Positive Early Breast Cancer | June 7, 2023 | July 1, 2031 |
| NCT05189067 | Recruiting | Phase 2/Phase 3 | Efficacy and Safety of Adjuvant Docetaxel and Trastuzumab in Stage I HER2-positive Breast Cancer | January 31, 2022 | June 30, 2025 |
| NCT05638594 | Recruiting | Phase 2 | Pyrotinib Combined With Trastuzumab, Dalpiciclib, Letrozole Versus TCbHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HR +/HER2 + Breast Cancer | December 20, 2022 | December 10, 2027 |
| NCT06162559 | Recruiting | Phase 1 | Neoadjuvant Trastuzumab, Pertuzumab and Tucatinib Without Chemotherapy in HER2-positive Breast Cancer: the TRAIN-4 Study | December 18, 2023 | May 2036 |
| NCT05900206 | Recruiting | Phase 2 | Trastuzumab Deruxtecan Versus Standard Neoadjuvant Treatment for HER2-positive Breast Cancer | October 26, 2023 | April 30, 2032 |
| NCT05188313 | Recruiting | Phase 3 | TRAstuzumab and Pertuzumab for HER2+ Resectable Oesophageal Cancer | March 9, 2022 | February 2037 |
| NCT06217185 | Recruiting | Phase 4 | The Efficacy and Safety of Pyrotinib, Trastuzumab Combined With Taxanes in the Treatment of Trastuzumab-treated HER2+ Advanced Breast Cancer (ABC). | January 2, 2024 | June 30, 2027 |
| NCT05515796 | Recruiting | Phase 2 | Multi-omics Sequencing in Neoadjuvant Immunotherapy of Gastrointestinal Tumors | September 1, 2022 | December 31, 2025 |
| NCT05187182 | Recruiting | Phase 1 | CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer | June 2, 2023 | June 30, 2027 |
| NCT05180006 | Recruiting | Phase 2 | Impact of Neoadjuvant Immunotherapy in Early Stage Breast Cancer Before Standard Therapy | February 24, 2022 | February 2026 |
| NCT03765983 | Recruiting | Phase 2 | GDC-0084 in Combination With Trastuzumab for Patients With HER2-Positive Breast Cancer Brain Metastases | February 11, 2019 | November 30, 2025 |
| NCT05170256 | Recruiting | Phase 2 | Trastuzumab and Standard Treatment With Chemo- and Immunotherapy as First Line Treatment for HER2 Positive Esophageal Squamous Cell Carcinoma Patients | February 4, 2022 | January 2025 |
| NCT06239467 | Recruiting | Phase 1 | First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer | March 1, 2024 | August 1, 2027 |
| NCT05152147 | Recruiting | Phase 3 | A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers | December 2, 2021 | February 1, 2026 |
| NCT03820141 | Recruiting | Phase 2 | Durvalumab With Trastuzumab and Pertuzumab in HER2-Enriched Breast Cancer | March 3, 2020 | February 2025 |
| NCT05132582 | Recruiting | Phase 3 | A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer | March 7, 2022 | June 30, 2027 |
| NCT05002127 | Recruiting | Phase 2/Phase 3 | A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06) | January 15, 2022 | August 2028 |
| NCT05458674 | Recruiting | Phase 2 | Tucatinib+Trastuzumab+Eribulin in HER2+ MBC | January 1, 2024 | August 1, 2027 |
| NCT04120246 | Recruiting | Phase 1 | Alpha-TEA and Trastuzumab for the Treatment of Refractory HER2+ Metastatic Breast Cancer | April 8, 2020 | February 1, 2025 |
| NCT04150640 | Recruiting | Phase 2 | Oxaliplatin and Liposomal Irinotecan (Plus Trastuzumab for HER2-positive Disease) in Advanced Esophageal and Gastric Adenocarcinoma | July 13, 2020 | December 2026 |
| NCT04993014 | Recruiting | Phase 2 | Circulating Tumor Cells and Treatment De-escalation After Neoadjuvant Therapy for HER2 Positive Breast Cancer | March 1, 2021 | April 30, 2028 |
| NCT05420467 | Recruiting | Phase 4 | A Study for the Adjuvant Treatment of Breast Cancer | July 10, 2022 | December 20, 2027 |
| NCT01785420 | Recruiting | Phase 3 | Pre Operative Trastuzumab in Operable Breast Cancer | May 2013 | February 2027 |
| NCT05978648 | Recruiting | Phase 2 | Trilaciclib in Patients With Early-Stage HR-negative Breast Cancer Receiving Adjuvant Chemotherapy | September 20, 2023 | December 31, 2027 |
| NCT04193059 | Recruiting | Phase 3 | Study Comparing EC-T Verses PCb in the Adjuvant Chemotherapy of Non-triple Negative Breast Cancer | August 1, 2018 | July 2024 |
| NCT04197687 | Recruiting | Phase 2 | TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery | February 20, 2020 | January 15, 2025 |
| NCT06328738 | Recruiting | Phase 1 | ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer | June 1, 2024 | July 2028 |
| NCT04928261 | Recruiting | Phase 4 | Evaluating 6-months of HER2-targeted Therapy in Patients With HER2 Positive Early-stage Breast Cancer That Achieve a Pathological Complete Response to Neoadjuvant Systemic Therapy | December 13, 2021 | September 2025 |
| NCT01817452 | Recruiting | Phase 2 | A Prospective, Randomized Multicenter, Open-label Comparison of Preoperative Combination of Trastuzumab and Pertuzumab With or Without Concurrent Taxane Chemotherapy Given for Twelve Weeks in Patients With Operable HER2+/HR- Breast Cancer Within the ADAPT Protocol | March 2014 | October 2024 |
| NCT04253561 | Recruiting | Phase 1 | Ipatasertib + Pertuzumab +Trastuzumab in Advanced HER2+ PI3KCA-mutant Breast Cancer Patients | February 25, 2020 | August 25, 2025 |
| NCT04886531 | Recruiting | Phase 2 | Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers | July 21, 2022 | May 2024 |
| NCT04266249 | Recruiting | Phase 2 | CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy | March 13, 2020 | December 31, 2038 |
| NCT04873362 | Recruiting | Phase 3 | A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy | May 4, 2021 | October 2, 2034 |
| NCT04819971 | Recruiting | Phase 2 | Study of Perioperative Chemotherapy Combined With Tislelizumab and Trastuzumab in the Treatment of GC/EGC | December 1, 2021 | December 31, 2025 |
| NCT05605509 | Recruiting | Phase 2 | RP-6306 in Patients With Advanced Cancer | May 24, 2023 | June 2025 |
| NCT04092673 | Recruiting | Phase 1/Phase 2 | Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies | October 25, 2019 | March 31, 2025 |
| NCT05076695 | Recruiting | Phase 2 | Neoadjuvant With Trastuzumab, Pyrotinib Plus Palbociclib and Fulvestrant in HER2-positive, ER-positive Breast Cancer | October 15, 2021 | October 15, 2024 |
| NCT05062889 | Recruiting | Phase 2 | Exploiting Circulating Tumour DNA to Intensify the Postoperative Treatment Resected Colon Cancer Patients | May 17, 2023 | December 2027 |
| NCT05041842 | Recruiting | Phase 2 | Treatment With Tucatinib in Patients With an Isolated Brain Progression of a Metastatic Breast Cancer | December 17, 2021 | March 30, 2026 |
| NCT05020860 | Recruiting | Phase 2 | Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer | April 18, 2023 | November 2029 |
| NCT06253871 | Recruiting | Phase 1 | A Phase 1/1b Study of IAM1363 in HER2 Cancers | March 25, 2024 | April 2028 |
| NCT03432741 | Suspended | Phase 1 | Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer | March 27, 2018 | May 1, 2026 |
| NCT04419181 | Suspended | Phase 2 | Feasibility of Chemotherapy De-escalation in Early-Stage HER2 Positive Breast Cancer | August 11, 2024 | June 1, 2026 |
| NCT03894007 | Terminated | Phase 2 | Improving Pre-operative Systemic Therapy for Human Epidermal Growth Factor Receptor 2 (HER2) Amplified Breast Cancer | May 23, 2019 | June 30, 2021 |
| NCT01388647 | Terminated | Phase 1/Phase 2 | Study of Neoadjuvant Carboplatin, Eribulin and Trastuzumab for Operable HER2 Positive Breast Cancer | August 2011 | September 2014 |
| NCT02593708 | Terminated | Phase 1 | Phase1 of Neratinib+Trastuzumab, Pertuzumab, Paclitaxel in Patients With Advanced Solid Tumors/HER2+ | November 3, 2015 | July 31, 2017 |
| NCT02598310 | Terminated | Phase 2 | Neoadjuvant Nab-PTX and Trastuzumab for ER Negative and HER2 Positive Breast Cancer | November 2015 | November 30, 2018 |
| NCT02598427 | Terminated | Phase 1 | Intrathecal Pertuzumab and Trastuzumab in Patients With New Untreated Asymptomatic or Low Symptomatic Brain Metastasis in HER2 Positive Breast Cancer | May 1, 2017 | February 22, 2018 |
| NCT01254136 | Terminated | Phase 1/Phase 2 | Safety and Efficacy of INCB007839 With Trastuzumab and Vinorelbine in Patients With Metastatic HER2+ Breast Cancer | October 2010 | October 2011 |
| NCT01220128 | Terminated | Phase 2 | Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer | April 11, 2011 | November 14, 2014 |
| NCT02726399 | Terminated | Phase 2 | Phase II Study of Ramucirumab With Chemotherapy in Patients With Metastatic Gastroesophageal Junction and Gastric Cancer | March 18, 2016 | February 26, 2019 |
| NCT02774681 | Terminated | Phase 2 | Palbociclib in Treating Patients With Metastatic HER-2 Positive Breast Cancer With Brain Metastasis | August 31, 2016 | February 16, 2020 |
| NCT02907918 | Terminated | Phase 2 | Neoadjuvant Study of Palbociclib in Combination With Letrozole and Trastuzumab in Stage II-III ER+ HER2+ Breast Cancer | June 30, 2017 | September 23, 2020 |
| NCT01187381 | Terminated | An Observational Study of the Mean Duration of Trastuzumab (Herceptin) Treatment in Participants With Early or Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer | April 14, 2010 | October 15, 2015 | |
| NCT01185509 | Terminated | Phase 2 | Trastuzumab and Vinorelbine in Advanced Breast Cancer | November 2010 | January 2018 |
| NCT01132664 | Terminated | Phase 1/Phase 2 | Phase 1b/2 Study of BKM120 Plus Trastuzumab in Patients With HER2-positive Breast Cancer | May 2010 | August 2014 |
| NCT00968968 | Terminated | Phase 3 | Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone | January 20, 2010 | March 30, 2018 |
| NCT00963547 | Terminated | Phase 1 | A Study of MK-2206 in Combination With Trastuzumab and Lapatinib for the Treatment of HER2+ Solid Tumors (MK-2206-015) | September 15, 2009 | December 22, 2011 |
| NCT00954512 | Terminated | Phase 1/Phase 2 | Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004) | September 25, 2009 | June 7, 2011 |
| NCT00864175 | Terminated | Phase 1/Phase 2 | Open Label Trial of INCB07839 to Determine Effect and Safety of INCB007839 Plus Trastuzumab in HER2 Positive Metastatic Breast Cancer | July 2007 | October 2011 |
| NCT00824733 | Terminated | Phase 2 | Agatolimod and Trastuzumab in Treating Patients With Locally Advanced or Metastatic Breast Cancer | February 2009 | April 2014 |
| NCT03329378 | Terminated | Phase 2 | Neoadjuvant Dose-Dense For Early Her2Neu Positive Breast Cancer | January 24, 2019 | March 7, 2021 |
| NCT00817362 | Terminated | Phase 2 | Efficacy and Safety of IPI-504 With Trastuzumab Pretreated, Locally Advanced or Metastatic HER2 Positive Breast Cancer | March 2009 | May 2011 |
| NCT00810017 | Terminated | Phase 2 | Phase 2 Study of Trastuzumab and Etoposide for Her2 Positive Breast Cancer | February 2009 | June 2010 |
| NCT00674414 | Terminated | Phase 2 | Trastuzumab With or Without Everolimus in Treating Women With Breast Cancer That Can Be Removed By Surgery | April 2008 | |
| NCT00625898 | Terminated | Phase 3 | BETH Study: Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus Bevacizumab | April 2008 | July 2014 |
| NCT00567879 | Terminated | Phase 1/Phase 2 | A Trial of Panobinostat and Trastuzumab for Adult Female Patients With HER2 Positive Metastatic Breast Cancer (MBC) Whose Disease Has Progressed on or After Trastuzumab | April 2008 | May 2011 |
| NCT03680560 | Terminated | Phase 1 | Study of ACTR T Cell Product in Combination With Trastuzumab in Subjects With HER2-Positive Advanced Solid Tumor Cancers | March 13, 2019 | March 12, 2020 |
| NCT00520975 | Terminated | Phase 3 | Bevacizumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER-2/NEU | November 2007 | October 2015 |
| NCT04066790 | Terminated | Phase 2 | Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer | September 9, 2019 | April 30, 2020 |
| NCT00478140 | Terminated | Phase 2 | Trastuzumab in Treating Patients With Locally Advanced or Metastatic Gallbladder Cancer or Bile Duct Cancer That Cannot Be Removed by Surgery | May 2007 | November 2011 |
| NCT04102618 | Terminated | Early Phase 1 | A Window-of-opportunity Study of Pelareorep in Early Breast Cancer | March 29, 2019 | April 20, 2022 |
| NCT04108858 | Terminated | Phase 1/Phase 2 | Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Maintenance Treatment (Trastuzumab and Pertuzumab) After Initial Chemotherapy in a Phase Ib/II Trial for Advanced HER2 Positive Breast Cancer | May 20, 2021 | April 29, 2022 |
| NCT04168931 | Terminated | Phase 2 | Trastuzumab to Patients With Advanced Gastric Cancer With HER2 Positive Expression in CTC | January 1, 2020 | January 13, 2023 |
| NCT00427427 | Terminated | Phase 2 | Delayed Adjuvant Herceptin® Treatment in Patients With HER-2 Positive Breast Cancer | January 2007 | October 2007 |
| NCT00272987 | Terminated | Phase 3 | ErbB2 Over-expressing Metastatic Breast Cancer Study Using Paclitaxel, Trastuzumab, and Lapatinib | December 13, 2005 | October 21, 2019 |
| NCT00216073 | Terminated | Phase 2 | Capecitabine, Oxaliplatin and Trastuzumab in Treating Patients With HER2 Positive Metastatic Breast Cancer | March 2004 | October 2006 |
| NCT00216047 | Terminated | Phase 1/Phase 2 | PTK787 + Trastuzumab for HER2 Overexpressing Metastatic Breast Cancer | January 2005 | August 2006 |
| NCT00169104 | Terminated | Phase 2/Phase 3 | Effects of Granulocyte Colony-stimulating Factor (G-CSF), Trastuzumab, and Vinorelbine on Immune Cell Function | July 2002 | March 2009 |
| NCT04510285 | Terminated | Phase 2 | A Single-Arm Pilot Study of Adjuvant Pembrolizumab Plus Trastuzumab in HER2+ Esophagogastric Tumors With Persistent Circulating Tumor DNA Following Curative Resection | August 10, 2020 | December 30, 2022 |
| NCT00140140 | Terminated | Phase 1/Phase 2 | A Phase I/II Study of ABI-007 (Abraxane®, Nab®-Paclitaxel)and Vinorelbine in Patients With Stage IV (Metastatic) Breast Cancer | August 2005 | February 2008 |
| NCT00130507 | Terminated | Phase 2 | Benefit of Adding Trastuzumab to Second Line Chemotherapy in Breast Cancer Patients Previously Treated With Trastuzumab | November 4, 2005 | July 25, 2009 |
| NCT00126607 | Terminated | Phase 2 | Trastuzumab in Treating Patients With Metastatic or Recurrent Salivary Gland Cancer | July 2005 | |
| NCT00088985 | Terminated | Phase 2 | Vaccine Therapy, Trastuzumab, and Vinorelbine in Treating Women With Locally Recurrent or Metastatic Breast Cancer | January 2004 | October 2009 |
| NCT00079326 | Terminated | Phase 2 | Trastuzumab and Ixabepilone in Treating Women With HER2-Positive Metastatic Breast Cancer | January 2004 | October 2010 |
| NCT01873833 | Terminated | Phase 2 | Capecitabine, Cyclophosphamide, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With HER2-Positive Metastatic Breast Cancer | July 29, 2013 | March 2, 2021 |
| NCT01891357 | Terminated | Phase 2 | Phase II Trial to Validate Markers for a Response Evaluation of a Combined Therapy in Patients With HER2+ Breast Cancer | September 30, 2013 | November 16, 2016 |
| NCT01912963 | Terminated | Phase 2 | Phase II Study of Eribulin Mesylate, Trastuzumab, and Pertuzumab in Women With Metastatic, Unresectable Locally Advanced, or Locally Recurrent HER2-Positive Breast Cancer | September 2013 | December 2016 |
| NCT01779050 | Terminated | Phase 2 | Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Disseminated Tumor Cells | December 19, 2013 | September 1, 2021 |
| NCT01953926 | Terminated | Phase 2 | Basket Study of Neratinib in Participants With Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations | September 30, 2013 | January 2, 2023 |
| NCT05091528 | Terminated | Phase 1/Phase 2 | A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers | February 8, 2022 | July 7, 2022 |
| NCT01774851 | Terminated | Phase 2 | A Study of MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach | January 2013 | December 2015 |
| NCT02005484 | Terminated | Phase 2 | A Study of Herceptin (Trastuzumab) in Patients With Metastatic or Advanced Gastric Cancer With Disease Progression | January 2004 | February 2008 |
| NCT02013765 | Terminated | Phase 2 | A Study of Herceptin (Trastuzumab) Monotherapy in Patients With Metastatic Urothelial Cancer | January 2001 | January 2010 |
| NCT01705340 | Terminated | Phase 1 | Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery | September 2012 | |
| NCT00039455 | Terminated | Phase 1 | Trastuzumab and Flavopiridol in Treating Patients With Metastatic Breast Cancer | April 2002 | |
| NCT02144012 | Terminated | Phase 3 | A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine Versus the Combination of Trastuzumab Plus Docetaxel in Patients With HER2-positive Breast Cancer | June 2014 | January 2016 |
| NCT02154529 | Terminated | Phase 1/Phase 2 | Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer | May 2014 | September 13, 2015 |
| NCT05395052 | Terminated | Phase 1 | FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors | May 31, 2022 | August 11, 2023 |
| NCT01690325 | Terminated | Phase 2 | Imaging for Response Assessment of Neoadjuvant Chemotherapy in Primary Breast Cancer (GALADON) | September 2012 | November 2016 |
| NCT02213042 | Terminated | Phase 2 | Evaluation of Biomarkers Associated With Response to Subsequent Therapies in Subjects With HER2-Positive Metastatic Breast Cancer | October 24, 2014 | June 4, 2020 |
| NCT02213744 | Terminated | Phase 2/Phase 3 | MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients | July 2014 | June 2017 |
| NCT02229149 | Terminated | Phase 2 | Phase 2 Study of Standard Chemotherapy With Trastuzumab, Plus or Minus Pertuzumab, for Pre-treated Metastatic Breast Cancer | December 2014 | January 2022 |
| NCT01613482 | Terminated | Phase 3 | TraStuzumAb-Radiotherapy : Impact on the Cerebral Prevention | October 2007 | October 2012 |
| NCT02297230 | Terminated | Phase 1/Phase 2 | Locally Advanced Breast Cancer: Individualized Treatment Based On Tumor Molecular Characteristics | June 2002 | December 2, 2014 |
| NCT00016276 | Terminated | Phase 3 | Combination Chemotherapy, Surgery, and Radiation Therapy With or Without Dexrazoxane and Trastuzumab in Treating Women With Stage III or Stage IV Breast Cancer | May 2001 | |
| NCT02318901 | Terminated | Phase 1/Phase 2 | Pembrolizumab and Monoclonal Antibody Therapy in Advanced Cancer | October 2014 | August 2018 |
| NCT01512199 | Terminated | Phase 1/Phase 2 | Phase 1b/2 Study of U3-1287 in Combination With Trastuzumab Plus Paclitaxel in Newly Diagnosed Metastatic Breast Cancer (MBC) | November 2011 | January 28, 2015 |
| NCT02379585 | Terminated | Phase 1/Phase 2 | Fasting on Newly Diagnosed Breast Cancer | January 2013 | August 2015 |
| NCT02393248 | Terminated | Phase 1/Phase 2 | Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101) | February 27, 2015 | December 17, 2021 |
| NCT01402401 | Terminated | Phase 2 | Phase II of AUY922 in Second-line Gastric Cancer in Combination With Trastuzumab in HER2 Positive Patients | November 2011 | June 2013 |
| NCT00006015 | Terminated | Phase 2 | Combination Chemotherapy Plus Trastuzumab in Treating Patients With Advanced, Recurrent, or Metastatic Colorectal Cancer | May 2000 | February 2003 |
| NCT00004856 | Terminated | Phase 2 | Trastuzumab in Treating Patients With Previously Treated, Locally Advanced, or Metastatic Cancer of the Urothelium | July 2002 | |
| NCT02901301 | Unknown status | Phase 1/Phase 2 | Pembrolizumab, Trastuzumab, HER2 Positive Gastric Cancer | February 6, 2017 | October 2021 |
| NCT02836847 | Unknown status | Phase 2 | Molecularly Target Therapy With GEMOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma | July 2016 | December 2020 |
| NCT03925233 | Unknown status | Breast Cancer Treatment Based on Organ-like Culture | January 2, 2019 | December 15, 2021 | |
| NCT04639271 | Unknown status | Phase 2 | Pyrotinib, Trastuzumab And Abraxane in HER2-positive MBC With Brain Metastasis | January 1, 2021 | March 1, 2022 |
| NCT02214004 | Unknown status | Phase 2 | Neoadjuvant Trastuzumab and Letrozole for Postmenopausal Women | March 2015 | June 2019 |
| NCT04683445 | Unknown status | Efficacy and Safety of Eribulin in the Treatment of Advanced Breast Cancer | December 1, 2020 | December 31, 2023 | |
| NCT04717531 | Unknown status | Phase 2 | Pyrotinib as Neoadjuvant Agent for Non-objective Response HER2-positive Early Breast Cancer | June 3, 2021 | May 31, 2024 |
| NCT04296162 | Unknown status | Phase 2 | Oral Vinorelbine or Capecitabine Combined With Trastuzumab as Adjuvant Treatment for Patients With Lymph Node Negative, HER-2 Positive and Small Tumor Size Breast Cancer (ORCHID) | March 1, 2019 | May 30, 2021 |
| NCT04290793 | Unknown status | Phase 2/Phase 3 | Neoadjuvant Chemotherapy With Pyrotinib, Epirubicin and Cyclophosphamide Followed by Taxanes and Trastuzumab for HER-2+ Breast Cancer | March 1, 2020 | March 1, 2024 |
| NCT00367250 | Unknown status | Phase 1 | Safety Study of Combined Immunotherapy With Trastuzumab and Cetuximab in Patients With Metastatic Breast Cancer | July 2006 | June 2011 |
| NCT04281576 | Unknown status | N/A | Effect of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Chemotherapy as First Line Treatment of Unresectable Gastroesophageal Junction or Gastric Adenocarcinoma | December 19, 2019 | September 2021 |
| NCT01850628 | Unknown status | NSABP Biospecimen Discovery Project | July 2013 | February 2022 | |
| NCT04236310 | Unknown status | Phase 2 | A Study of Neoadjuvant SHR6390 in Combination With Anastrozole, Pyrotinib, and Trastuzumab in Patients With ER+/HER2+ Breast Cancer. | January 15, 2020 | December 31, 2022 |
| NCT02238509 | Unknown status | Phase 2 | Safety and QoL of Trastuzumab With Lapatinib or Chemiotherapy in MBC and HER2+ Patients Refractory to Anti HER2 Therapies | November 2014 | October 2017 |
| NCT00398437 | Unknown status | N/A | Magnetic Resonance Imaging for the Early Detection of CNS Metastases in Women With Stage IV Breast Cancer | September 2006 | |
| NCT01880385 | Unknown status | Phase 1 | Efficacy and Safety of Bevacizumab in the Neodjuvant Treatment of Inflammatory Breast Cancer | March 2011 | April 2017 |
| NCT02250209 | Unknown status | Phase 2 | T- XELOX in HER2-positive Stage III Gastric Cancer After D2 Gastrectomy | July 2014 | December 2017 |
| NCT00398489 | Unknown status | Phase 2 | Docetaxel, Epirubicin, and Cyclophosphamide With or Without Trastuzumab in Treating Women With Locally Advanced Breast Cancer That Can Be Removed By Surgery | October 2006 | |
| NCT00430001 | Unknown status | Phase 3 | Vinorelbine Plus (+) Trastuzumab vs Docetaxel Plus (+) Trastuzumab as 1 Line Treatment for HER2 Positive (+) Metastatic Breast Cancer | May 2005 | December 2008 |
| NCT04961307 | Unknown status | Evaluation of Heart Function in Breast Cancer Patients Using Trastuzumab | July 5, 2019 | December 30, 2021 | |
| NCT04962425 | Unknown status | Risk Assessment Model of Trastuzumab-related Cardiotoxicity in Breast Cancer Patients | January 8, 2021 | December 30, 2021 | |
| NCT04152057 | Unknown status | Phase 1/Phase 2 | Pyrotinib Maleate Tablets Combined With Albumin Paclitaxel and Trastuzumab for Her2-positive Breast Cancer | November 2019 | April 2021 |
| NCT04088110 | Unknown status | Phase 2 | Pyrotinib Combined With Trastuzumab Plus Aromatase Inhibitor in Treatment of Breast Cancer | November 2019 | November 2023 |
| NCT04034823 | Unknown status | Phase 2 | KN035 in Combination With Trastuzumab and Docetaxel in HER2-positive Breast Cancer | September 1, 2019 | January 1, 2022 |
| NCT03994107 | Unknown status | Phase 1/Phase 2 | Pegylated Liposomal Doxorubicin Plus Albumin-Bound Paclitaxel and Trastuzumab in HER-2 Positive Breast Cancer | October 1, 2019 | January 1, 2021 |
| NCT03910712 | Unknown status | Phase 2 | Pyrotinib Combined With Trastuzumab and AI in the First-line Treatment of HER2 Positive/ HR Positive MBC | June 1, 2019 | December 1, 2023 |
| NCT02514681 | Unknown status | Phase 3 | A Phase III Trial of Pertuzumab Retreatment in Previously Pertuzumab Treated Her2-Positive Advanced Breast Cancer | August 1, 2015 | December 2021 |
| NCT05429684 | Unknown status | Phase 3 | Precise Therapy for Refractory HER2 Positive Advanced Breast Cancer | January 1, 2021 | February 28, 2024 |
| NCT03756064 | Unknown status | N/A | Neoadjuvant Study of Pyrotinib in Patients With HER2 Positive Breast Cancer | August 1, 2019 | July 31, 2021 |
| NCT02656589 | Unknown status | microRNA of Human Epidermal Growth Factor Receptor 2 （HER2）Positive Patient Treated With Herceptin | June 2015 | June 2018 | |
| NCT00486668 | Unknown status | Phase 3 | A Study of AC Followed by a Combination of Paclitaxel Plus Trastuzumab or Lapatinib or Both Given Before Surgery to Patients With Operable HER2 Positive Invasive Breast Cancer | July 2007 | March 2017 |
| NCT00533936 | Unknown status | Phase 2 | Trastuzumab or Observation After Combination Chemotherapy and Trastuzumab in Treating Patients Undergoing Surgery for Stage II or Stage III Breast Cancer | September 2006 | |
| NCT00003797 | Unknown status | Phase 2 | Gemcitabine and Monoclonal Antibody Therapy in Treating Patients With Metastatic Cancer of the Pancreas | March 1999 | |
| NCT03588533 | Unknown status | Phase 2 | Herzuma-capecitabine/Cisplatin for Gastric Cancer | June 10, 2018 | August 31, 2021 |
| NCT03588091 | Unknown status | Phase 3 | Neoadjuvant Study of Pyrotinib in Combination With Trastuzumab in Patients With HER2 Positive Breast Cancer | July 24, 2018 | June 2022 |
| NCT00629278 | Unknown status | Phase 3 | Combination Chemotherapy and Trastuzumab in Treating Women With Stage I, Stage II, or Stage III HER2-Positive Breast Cancer | December 2007 | |
| NCT03521245 | Unknown status | Molecular Pathway Activation Markers Predicting Efficacy of Trastuzumab Therapy for HER2-positive Breast Cancer | October 1, 2017 | May 1, 2022 | |
| NCT00637325 | Unknown status | Phase 3 | Trastuzumab Optimization Trial in Breast Cancer | November 2007 | April 2011 |
| NCT03457896 | Unknown status | Phase 2 | Study of Neratinib +Trastuzumab or Neratinib + Cetuximab in Patients With KRAS/NRAS/BRAF/PIK3CA Wild-Type Metastatic Colorectal Cancer by HER2 Status | May 18, 2018 | September 30, 2022 |
| NCT00712140 | Unknown status | Phase 3 | Trastuzumab in Treating Women With HER2-Positive Early Breast Cancer | October 2007 | |
| NCT03368131 | Unknown status | Phase 2 | Concurrent Neoadjuvant Chemoradiotherapy Plus Trastuzumab in the Treatment of Siewert II ，III of Human Epidermal Growth Factor Receptor-2(HER-2) Positive Gastroesophageal Junction Adenocarcinoma： A Randomized, Controlled Clinical Study | December 1, 2017 | December 31, 2020 |
| NCT03367676 | Unknown status | Phase 2 | 12 weekS Adjuvant dOcetaxel Plus trastuzumaB in Patients With Small, Node-negative, HER2-positive Breast cancER (SOBER) | December 30, 2017 | June 1, 2021 |
| NCT02638428 | Unknown status | Phase 2 | Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy | December 2015 | December 2023 |
| NCT03273595 | Unknown status | Phase 2 | Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive Breast Cancer | July 2016 | December 2019 |
| NCT03264547 | Unknown status | Phase 3 | A Study to Compare Eribulin Mesylate + Pertuzumab + Trastuzumab With Paclitaxel or Docetaxel + Pertuzumab + Trastuzumab | August 28, 2017 | October 31, 2023 |
| NCT03239015 | Unknown status | Phase 2 | Efficacy and Safety of Precision Therapy in Refractory Tumor | January 1, 2017 | December 31, 2023 |
| NCT02689921 | Unknown status | Phase 2 | NEOADjuvant Aromatase Inhibitor and Pertuzumab/Trastuzumab for Women With Breast Cancer | April 2016 | December 2018 |
| NCT01428414 | Unknown status | Phase 2 | Efficacy and Safety Study of Trastuzumab and Paclitaxel Based Regimens to Treat HER2-positive Breast Cancer | August 2011 | February 2015 |
| NCT02510781 | Unknown status | Phase 2 | A Study on Neoadjuvant Therapy for Her-2 Positive Breast Cancer and the Prognosis by Detecting CTCs | January 2015 | December 2017 |
| NCT04609540 | Unknown status | Pyrotinib Combined With Trastuzumab And Chemotherapy in HER2-positive MBC | January 1, 2021 | June 1, 2022 | |
| NCT00054470 | Withdrawn | Phase 2 | Tipifarnib Plus Trastuzumab in Treating Patients With Metastatic Breast Cancer | December 2002 | January 2003 |
| NCT00057993 | Withdrawn | Phase 2 | Trastuzumab and Exemestane in Treating Postmenopausal Women With Metastatic or Locally Advanced Breast Cancer | July 2002 | August 2004 |
| NCT02735798 | Withdrawn | Early Phase 1 | 64-Cu Labeled Brain PET/MRI for MM-302 in Advanced HER2+ Cancers With Brain Mets | April 2016 | June 2018 |
| NCT00053339 | Withdrawn | Phase 3 | Trastuzumab With or Without Tamoxifen in Treating Women With Progressive Stage IV Breast Cancer | ||
| NCT02569489 | Withdrawn | Phase 1 | Dose Escalation Study of HBI-8000 in Combination With Paclitaxel and Trastuzumab in Women With Advanced or Metastatic HER2+ Breast Cancer | December 2015 | December 2015 |
| NCT03846583 | Withdrawn | Phase 1 | Tucatinib + Abemaciclib + Herceptin for HER2+ MBC | June 28, 2020 | September 22, 2020 |
| NCT03811418 | Withdrawn | Phase 3 | A Study to Compare Pertuzumab + Trastuzumab + Vinorelbine vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-positive Metastatic Breast Cancer | January 2019 | April 2019 |
| NCT02102438 | Withdrawn | N/A | Chemotherapy for Elderly Patients Diagnosed With Localized HER2 Positive Breast Cancer | April 2014 | April 2018 |
| NCT03766607 | Withdrawn | Phase 2 | Trastuzumab Beyond Progression in HER2 Positive Metastatic Gastric Cancer | September 30, 2019 | June 30, 2022 |
| NCT01679743 | Withdrawn | Phase 2 | GRN1005 for Brain Metastases From Breast or Lung Cancer | August 29, 2012 | August 11, 2014 |
| NCT01137994 | Withdrawn | Phase 2 | A Phase II, Randomized, Open-label Study of Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive and p95HER2-positive Metastatic Breast Cancer | October 2011 | March 2018 |
| NCT01205217 | Withdrawn | Phase 2 | Lapatinib or Trastuzumab Given Prior to Surgery With Chemotherapy in Patients With Early Breast Cancer | December 2010 | December 2010 |
| NCT00397501 | Withdrawn | Phase 1/Phase 2 | BBBD Followed By Methotrexate and Carboplatin With or Without Trastuzumab in Treating Women With Breast Cancer That Has Spread to the Brain | October 2013 | October 2013 |
| NCT04512261 | Withdrawn | Phase 1/Phase 2 | TOPAZ: Tucatinib in COmbination With Pembrolizumab And TrastuZumab in Patients With HER2-Positive Breast Cancer Brain Metastases | June 1, 2022 | June 1, 2024 |
| NCT01427244 | Withdrawn | Phase 2 | Evaluation of Trastuzumab In Patients With HER2 Positive Persistent Or Recurrent Vulvar Paget's Disease | August 2011 | September 2015 |
| NCT01479179 | Withdrawn | Phase 1/Phase 2 | Trastuzumab in Combination With AMG 479 in HER-2 Overexpressing MBC Progressing on Trastuzumab | November 2012 | |
| NCT01557764 | Withdrawn | Phase 2 | Lapatinib With Trastuzumab in Treating Patients With HER2-Negative/HER2 Mutant Metastatic Breast Cancer | September 2012 | March 2016 |
| NCT02336984 | Withdrawn | Phase 1/Phase 2 | A Phase I/II Trial of HER-2/Neu Pulsed DC1 Vaccine Combined With Trastuzumab for Patients With DCIS | June 2014 | April 4, 2016 |
| NCT00006123 | Withdrawn | Phase 1/Phase 2 | Chemotherapy and Peripheral Stem Cell Transplantation Followed by Trastuzumab in Treating Women With Metastatic Breast Cancer | July 2000 | July 2000 |
| NCT05238831 | Withdrawn | Early Phase 1 | SMMART Adaptive Clinical Treatment (ACT) Trial | January 30, 2023 | May 31, 2026 |
| NCT04464967 | Withdrawn | Phase 1/Phase 2 | Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers | March 2021 | February 2023 |
| NCT00434031 | Withdrawn | Phase 2 | CETRA: Neoadjuvant Caelyx and Trastuzumab in Her-2 Positive Breast Cancer | September 2007 |
- Trade name (Drug list of Screening Committee of Anticancer Drugs)
- Herceptin
- US Approved Year (20160209) (Drug list of Screening Committee of Anticancer Drugs)
- 1998
- Japan Approved Year (20160209) (Drug list of Screening Committee of Anticancer Drugs)
- 2001
- Target (Drug list of Screening Committee of Anticancer Drugs)
- Her2
- Disease name (Drug list of Screening Committee of Anticancer Drugs)
- 乳がん
- Disease name (Drug list of Screening Committee of Anticancer Drugs)
- 胃がん